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ABSTRACT 
Tapp, Katherine N. Ph.D., Purdue University, December 2014. Evaluation of Yttrium-90 
Positron Emission Dosimetry. Major Professor: Gary Hutchins 
 
 
Purpose:  Radioembolization is a novel treatment which utilizes the liver’s unique dual 
system blood supply to trap yttrium-90 (90Y) microspheres in microvasculature near liver 
tumors. Radioembolization dose planning and dosimetry are based on crude, inaccurate 
assumptions due to the lack of knowledge of patient specific 90Y microsphere 
distribution. In recent years, the very small 3.1867e-5 internal pair production decay 
branch of 90Y has been shown to allow for positron emission tomography (PET) imaging 
following radioembolization.  This work explores the accuracy and limitation of 90Y PET 
imaging due to the extremely low signal to noise (SNR) ratio associated with 90Y and 
verifies the accuracy of using these PET images for 3-dimensional (3D) dosimetry. 
Material and Methods: PET acquisitions of a phantom containing 90Y filled cylindrical 
inserts were acquired to determine quantitative accuracy of the PET images to measure 
90Y activity.  Numerous reconstruction algorithms were used to determine the optimal 
protocol to balance image noise and accuracy. A GATE model of the PET scanner was 
used to evaluate the origin of prompt signal and random noise coincidence counts in these 
PET acquisitions. PET images were converted to dose maps using standard S-kernel 
convolution. Polymer gel dosimetry was used to validate the 3D dose map results.  
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Furthermore, PET, with associated CT images, were used as input data into MC 
simulations to model dose rates surrounding patients for future patient release studies.  A 
Siemens® Biograph 64 TruePoint PET/CT was used for all acquisitions and 
reconstructions.  
Results: The phantom study determined Siemens® OSEM-PSF algorithm, known as 
TrueX, with 2 iterations and 14 subsets had the optimal balance of noise and accuracy. 
Using this reconstruction algorithm, the PET images were found to accurately measure 
activity and calculated dose within 10% when 90Y concentration was above the minimum 
detectable concentrations (MDC) of 1 MBq/ml.  However, this reconstruction algorithm 
was shown to have a positive bias in areas where concentration was below the MDC due 
to truncation of negative sinogram bin values caused by statistical noise in the random 
correction.  Polymer gel dosimetry verified the accuracy of PET dose maps but also 
identified a limitation in cases of highly gradient distributions due to the PET spatial 
resolution spreading of measured activity.  Additionally, external dose rates were found 
to be accurately predicted through use of 90Y PET/CT images as inputs into a MC 
simulation.   
Conclusion:  Research in 90Y PET/CT has quickly been expanding over recent years as a 
feasible method to provide liver distribution of 90Y following radioembolization.  This 
study demonstrates the accuracy and limitations of the use of these 90Y PET/CT images 
in patient specific qualitative dosimetry. 
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CHAPTER 1. INTRODUCTION 
1.1 Introduction 
Hepatocellular carcinoma (HCC) is the sixth most prevalent type of cancer and is the 
third leading cause of cancer-related deaths worldwide(1). It is estimated that there are 1 
million cases of HCC worldwide and its incidence is expected to increase due to growing 
Hepatitis C prevalence and HCC’s link to Hepatitis C induced cirrhosis(2). Surgical 
resection, liver transplantation, and percutaneous ablation are highly effective treatment 
options for patients in early stages of the disease but these treatment options are limited 
to 25 to 40% of patients in the US who do not have advanced stage HCC at the time of 
diagnosis(3). In the past, a majority of the patients with advanced disease had limited 
therapeutic treatment options because HCC is multidrug and radiation resistant compared 
to the surrounding normal liver parenchyma tissue(4).  
Radioembolization is a novel form of brachytherapy in which embolic microspheres 
loaded with 90Y are administered via an intraarterial injection.  For the treatment of liver 
tumors, including HCC, 90Y microspheres are administered into the hepatic artery and 
travel downstream in the vasculature where they become trapped in the liver capillary 
beds due to their 20 – 30 μm diameter(5).  90Y is used as the therapeutic radionuclide 
because it is almost a pure beta emitter, which is able to irradiate tissues over a short 
average distance of 2.5 mm (11 mm maximum) while sparing the remaining liver and 
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extra-hepatic tissues.  The goal of the treatment is for the microspheres to become lodged 
within the tumor vasculature, where they provide a large absorbed dose to the tumor 
volume leading to cell death and destruction of essential tumor vascular, while 
maintaining the dose to normal surrounding liver tissue below cytotoxic levels. This 
therapeutic objective is normally achieved because to the hepatic artery supplies 
approximately 80-100% of the blood flow to the tumor, while supplying only 20-30% of 
blood flow to the normal healthy liver tissue(6). 
Radioembolization currently is considered a late stage treatment and used only after 
patients have exhausted all other standard treatment options.  The treatment goals are to 
increase time to tumor progression, extend overall survival, and improving quality of life. 
Radioembolization has been shown to increase patient median survival compared to 
historical treatment controls, with one 80 patient study demonstrating an increase from 
244 and 64 days to 649 and 302 days for Okuda I and II patients, respectively(7).  
Additionally, radioembolization has been used successfully as a bridge to transplantation 
therapy, with one 35 patient study demonstrating 65% of patients were downstaged to 
transplantation, resection, or radiofrequency ablation(8).   
Radioembolization can result in severe complications due to radiation damage to healthy 
liver. Radioembolization induced liver disease (ReILD)occurs if too much healthy tissue 
receives a high level of radiation exposure  and liver function is destroyed, sometimes 
leading to death(5). ReILD has been difficult to classify, but one study defines it as 
jaundice and ascites appearing 1 to 2 months after treatment without tumor progression or 
bile duct occlusion and may lead to death(9). Although ReILD is generally found only in 
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patients with cirrhosis or those who previously had chemotherapy, there is currently no 
method to predict which of these treatments may lead to ReILD. Unfortunately, there is 
currently no clinical method to predict which treatments will be a success and which ones 
may lead to complications.  
1.2 Background 
1.2.1 HCC Background 
In many cases, HCC arises from an underlying liver disease, such as Hepatitis B or C 
(HBV/HCV) and liver cirrhosis. Approximately 2 billion individuals have HBV 
worldwide, which is believed to lead to  96,000 to 160,000 HCC related deaths 
annually(10). The majority of HCC cases are believed to be linked to HCV induced liver 
cirrhosis(11).  Heavy alcohol consumption, which may also lead to cirrhosis, is a 
significant risk factor for HCC.  However, not all cases are associated with cirrhosis, with 
incidence in non-cirrhosis livers found to be between 10-50% in varying studies(12).  
HCC is a complex disease leading to large variations in morphology related to size and if 
surrounding liver is cirrhotic.  In cirrhotic livers, small tumors may be well demarcated 
with a fibrous capsule and advanced tumors are generally expansive and accompanied by 
intrahepatic metastases.  In non-cirrhotic livers, HCC tumors generally grow faster and 
larger, potentially infiltrating both liver lobes(12).  The large variations in HCC tumor 
types, with differences in liver function reserve due to presence or lack of cirrhosis, make 
it difficult to model HCC treatment outcomes in patient groups.  
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HCC is the primary cancer in the liver, which is the second largest organs in the body.  
Typical liver mass in a healthy adult is between 1.2 and 1.7 kg(13).  Its volume is divided 
into two lobes, with the right lobe generally containing about 70% of liver mass and the 
left lobe containing the remaining 30%(14).  The liver is made up of functional 
hexagonally shaped subunits known as lobules. The liver blood supply is delivered by 
two pathways, the portal vein and hepatic artery. The portal vein supplies the majority of 
the blood to, approximately 20-30%, to the healthy liver tissue.  Blood travels through 
branches of the portal vein and hepatic artery the central vein and then complex network 
of hepatic sinusoids found in each lobule.  Sinusoids make up the capillary network of the 
liver as they are the small blood vessels found between plates of hepatocytes which are 
one or two cells thick(15).  Blood travels through the sinusoids towards the periphery of 
the acinus, which is connected to the terminal hepatic venules.  The venules progressively 
turn into larger hepatic vein branches as the blood leaves the liver through the inferior 
vena cava(16).  
1.2.2 Yttrium-90 Microspheres 
90Y major decay pathway (>99.98%) is via a high energy  - decay to the stable ground 
state of 90Zr with a maximum energy of 2.28 MeV. This  - particle is the principle 
radiation of concern for the internal dosimetry of the patient as it irradiates tissue over its 
maximum range of 11 mm. The half-life of 90Y is 64.053 ± 0.020 hrs(17). 
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Figure 1.1Yttrium-90 Decay Scheme 
The remaining approximate 0.01% of decay occur via  - emission to an excited 0+ state 
of 90Zr, which immediately decays through internal pair production, internal conversion, 
or two photon de-excitation (figure 1.1).  The internal pair production was first predicted 
by Ford and verified by Johnson et al. in 1955, where the probability of pair production 
per decay was observed to be (2 ± 1)e-4.  This branching ratio as changed several times 
throughout the years as more sensitive detection equipment became available.  Most 
recently, Selwyn et al. found it to be (3.1857±0.047)e-5 using high purity germanium 
detectors measuring the annihilation photon coincidence(18).   
Currently, there are only two different manufacured types of 90Y microspheres available 
in North America, glass micropsheres from TheraSphere® and resin microshpheres from 
SIR-Sphere®.    Although similar in use, there are slight differences between the two.  
TheraSpheres are glass spheres with the Y incorporated inside its matrix, with the 90Y 
6 
 
being created from 89Y through reactor based neutron activition.  TheraSpheres® have a 
diameter of 20 to 30 μm and an average activity of 2500 Bq per sphere. For SIR-
Spheres®, the 90Y is encapsulated in resin surrounding the microsphere and have an 
average diameter of 35 μm and activity of 50 Bq per sphere(19).  Due to the difference in 
activity, substantially more particles are injected with SIR-Spheres® than TheraSpheres® 
during treatment. TheraSpheres® was the only microsphere used this work since it is the 
most common treatment used in recent years at Indiana University Health University 
Hosptital in Indianapolis, Indiana. However, imaging and dosimetry techniques, for all 
but impurity photons background noise discussed in chapter 3, should be directly 
applicable to SIR-Sphere® treatments as well.  
1.3 Clinical Procedure 
When radioembolization was first introduced, it had severe limitations due to some 
treatments having pulmonary shunting leading to pulmonary fibrosis and regional 
perfusion leading to gastrointestinal (GI) toxicity. To screen out patients who could have 
these complications, patients must now undergo a planning arteriogram to determine the 
amount of microspheres which leave the liver due to shunting. During this procedure, the 
Interventional Radiologist (IR) first performs targeted hepatic arterial catheterization 
during a planning angiogram to limit shunting.  The IR then injects 99mTc 
macroaggregated albumun (MAA) particles as a microsphere surrogate allowing for a 
diagnostic whole body gamma camera imaging or single photon emission computed 
tomography (SPECT) to predict the fraction of microspheres which will end up in the 
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lung due to shunting or perfusion into the GI tract. The lung shunt fraction (LSF) is 
determined based on the counts found in the lung (Clung) and liver (Cliver), 
Equation 1.1 
  

	

	

 

 . 
 The 99mTc MAA is used as a surrogate to predict extrahepatic distribution due to its 
similar size to the microspheres. The MAA particles are delivered by the IR through a 
catheter which is guided into the hepatic artery from the femoral artery under 
fluoroscopy.  A patient is excluded from treatment if the 99mTc-MAA predicts a potential 
shunt resulting in greater than 30 Gy to the lungs or any shunting to the GI tract that 
cannot be corrected by catheter embolization techniques(5). Additional treatment 
contradictions include excessive tumor burden with limited hepatic reserve, elevated total 
bilirubin level (> 2mg/dl) in the absence of a revisable cause, and compromised portal 
vein without the ability to conduct selective radioembolization(20).  
Approximately 2 weeks after the planning angiogram, the 90Y microspheres are delivered 
through a catheter which is placed in the similar location and manner as the MAA 
particles.  The IR injects the microspheres using a manufacturer designed administration 
apparatus which is designed to provide shielding from the 90Y dose vial.   
In current clinical practice, there are three common methods currently used to determine 
activity to be delivered. First,  the simpliest is the non-compartmental Medical Internal 
Radiation Dose (MIRD) method, which is described by the following equation: 
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Equation 1.2 
  


; 
where A is injected activity of 90Y in GBq, M is mass of the treated volume in kg whether 
it be the segment, lobe or whole liver, and D is the uniform dose in Gy to the treated 
volume.  This is the most commonly used method for TheraSphere® treatments, where 
the recommended dose to the entire volume is 80 to 120 Gy(5).     
There are two prescribed activity determinations described in the SIR-sphere® package 
insert(21).  First is the body surface area method (BSA), where activity is calculated 
based on the patients BSA as shown:  
Equation 1.3 
	   

  

 
  
Equation 1.4 
  

	   






ff
fi 
where A is again activity in GBq, h is height of the patient in m, w is weight in kg, and 


 and 
ff
 are tumor and treated liver volume, respectively. The second SIR-sphere 
method is the empiric method, which is based on the size of the tumor volume as shown 
in table 1.1. 
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Table 1.1Empirical dosimetry method for 90Y activity determination commonly used in 
SIRsphere® treatments 
Tumor Involvement in the Liver Prescribed Activity 
  25% 2 GBq 
25 – 50 % 2.5 GBq 
> 50% 3 GBq 
 
Following the treatment, it is recommended a post procedural imaging scan is 
recommended to qualitatively evaluate 90Y distribution to ensure minimal presence of 
extra-hepatic shunting.  In many institutions, this is completed through SPECT imaging 
of the - produced Bremsstrahlung photons.  PET imaging, as described below, has also 
started to be used in a few intuitions to provide this post procedural distribution map.  
1.4 Clinical Dosimetry 
Radioembolization is a unique form of radiotherapy.  The limited photon emission which 
makes 90Y advantageous for treatment, makes it clinically difficult to determine the 
source distribution on a patient specific basis.  Therefore, unlike sealed source 
brachytherapy and external radiotherapy, intra-organ dosimetry is generally not 
determined on a patient basis. Without a known source distribution, gross assumptions 
are necessary to determine patient dosimetry and large errors are expected in all of the 
following clinically used dosimetry methods currently being used.  
The first clinically used dosimetry method is based on the non-compartmental MIRD 
model.  The non-compartmental model assumes the microspheres are deposited 
homogeneously, and therefore provides a uniform dose to the treated lobe.  The dose is 
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then easily calculated by dividing the total 90Y energy released by the treated lobe mass, 
as described by the following equation,  
Equation 1.5 
  
 

 

	
, 
where k is conversion factor, 
 is cumulative activity, M is mass of the treated volume, 
and E is average energy per disintegration. Cumulative activity is determined as 
described below: 
Equation 1.6 






 

  

 




, 
where, A is the injected activity, and S is lung shunt percent fraction. Time is integrated 
to infinity because the microspheres become permanently lodged and are non-
biodegradable. Assuming activity in GBq and mass is in Kg, k is generally rounded to 50 
and the equation simplifies to: 
Equation 1.7 
  
fffi  
   
fl
ffi 
The assumption that the microspheres deposit uniformly used in this non-compartmental 
model is known to be false.  As described previously, microsphere deposition is generally 
preferentially delivered to the tumor volume because of tumor hypervascularity and 
higher proportion of hepatic artery blood supply as compared to normal liver tissue(22).  
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Therefore, is method generally underestimates tumor and overestimate normal tissue 
doses.  Additionally, it fails to provide any warning when preferential tumor deposition 
does not occur due to unique patient vasculature or a bad catheter position during 
administration. However, since there has not been a proven way to determine patient 
specific 90Y distribution, this currently is the most commonly used dosimetric method 
with TheraSphere® treatments.  
The second dosimetry method, known as the compartmental MIRD method or partition 
method, tries to estimate the difference in tumor and normal tissue microsphere 
distribution by defining them as two separate compartments. The difference in 
distribution is then modeled based on a tumor to normal tissue dose ratio (TNR), which 
uses the mass of the tumor (Mt) and normal tissue in the treatment volume (Mn) and 
activity (A) found in the pretreatment 99Tc-MAA SPECT as shown in the following 
equation,  
Equation 1.8 
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. 
Dose to the tumor and normal treated volume tissue is then determined from: 
Equation 1.9 
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Equation 1.10 
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This corrects for the difference in uptake between tumor and normal tissue assuming 
99Tc-MAA accurately predicts 90Y microsphere distribution.  However, there is only a 
few studies which have looked into the correlation between the distributions and results 
are varied.  It is believed the distributions may be mismatched due to differences in 
catheter position, injection techniques, particle size, flow during the injection, 
progression of the disease between injections, and differences in imaging techniques(23).  
The recommended post-procedural SPECT imaging is currently generally used to 
determine qualitative distribution to find gross problems such as extra-hepatic shunting. 
Research studies have emerged to try to assess the feasibility of using SPECT images to 
determine patient specific 90Y dose distributions(24, 25), but clinical quantitative images 
for dosimetric use have been difficult to generate due to the continuous energy spectrum 
and low spatial resolution associated with bremsstrahlung SPECT.  
1.5 90Y Positron Emission Tomography 
In 2004, Nickles et al. demonstrated 90Y positron emission tomography (PET) imaging is 
possible due to the internal pair production pathway(26).  This study demonstrated 90Y 
activity can be quantified from PET through imaging a Derenzo phantom using a bismuth 
germinate (BGO) crystal micro-PET scanner. In 2009, Llommel et al. published the first 
patient PET image using a Time of Flight (TOF) with lutetium-yttrium-oxyorthosilicate 
(LYSO) crystals(27).  Following publication of this image, several studies have 
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demonstrated the feasibility of using PET/CT images for quantitative images(28-31).   
Many studies have even shown feasibility of using these PET images for patient specific 
dosimetry following radioembolization(32-34).  
Due to the low positron emission rate and bremsstrahlung photon emission,  90Y creates 
an extremely low signal to noise ratio (SNR).  This low SNR make 90Y a non-ideal PET 
radionuclide. Acquisition and reconstruction techniques are not expected to be the same 
as with other radionuclides, like 18F. Even though many groups have shown 90Y PET 
imaging feasibility, little work has been completed to validate the dose maps or analyze 
the influences PET acquisition and reconstruction methods have on accuracy. Once the 
90Y PET images are validated, it is believed they could be used to predict treatment 
response and normal liver complications such as ReILD, enhancing the efficiency and 
safety of SIRT.  Therefore, the aims of this study are to provide evaluation and validation 
of 90Y PET imaging and are expressed below:   
1) Evaluate the effects various reconstructions algorithms have on the accuracy 
and limitations of 90Y PET/CT imaging. 
2) Determine origin of 90Y PET coincident count signal and noise to support 
appropriate reconstruction techniques.  
3) Evaluate the effect of positive bias observed in 90Y PET/CT using standard 
clinical iterative algorithm techniques for reconstruction following sinogram 
truncation.  
4) Validate 90Y PET/CT dose maps created using a standard S-kernel using gel 
dosimetry. 
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5) Use PET/CT 90Y activity distribution maps to verify line source assumption 
used in patient release surveys. 
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CHAPTER 2. ACCURACY AND LIMITATIONS OF VARIOUS PET 
RECONSTRUCTION TECHNIQUES FOR 90Y IMAGING  
2.1 Introduction 
2.1.1 PET Acquisition 
PET images are created by detection of the two 511 keV photons produced  by 
positronium (positron-electron pair) annihilation.  The annihilation photons are detected 
by scintillation crystals, which convert photon iteraction into light.  The light signal is 
then multiplied in coupled photomultiplier tubes (PMT) attached to a block of crystals.  
The distribution of the light across the PMTs enables the determination of the location of 
the incident photon. The electronic signal produced by the PMT is proportional to the 
energy deposited during the photons interaction with the crystal.   
The detection of one photon is often described as a single event. For a coincidence event 
to be recorded, 2 single events must be detected within a short time window, generally 
around 4-6 ns.  These coincident events are known as a prompt events and are recorded 
as lines of response (LOR) defined by pairs of detetor elements.  When the coincedent 
event represents the detection of both photons from a single positron annihilation which 
had no previous interaction, such as compton scattering, they are called true events 
(trues). The LOR associated with a true event will overlap with  location of the source 
because annihilation photons are emitted approximately 180° apart (figure 2.1). In 
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addition to trues events, there are also unwanted scattered and random coincidence 
events.  Scattered events occur when one or both of the annihilation photons undergo 
Compton interactions before they reach the detector but still maintain enough energy to 
be accepted in the PET energy window.  The PET energy window is based around 511 
keV, the energy of an annihilation photon.  The exact width of the energy window is set 
for each type of scanner to balance the scanners sensitivity to true annihilation events and 
minimize the acceptance of scatter events. Random  coincidence events occur when two 
photons not associated with a distinct positronium annihilation events are detected within 
the coincidence time window.  Photons which cause random events may or may not be 
from a positronium annihilation events.  Background noise is limited in PET scanning 
due to the use of thick lead or tungsten shielding around the detectors and the energy and 
coincencedence time windows. 
 
Figure 2.1 LOR (black line) and photon path (yellow line) based on true, scattered (blue 
star), and random PET detection events (red star).  
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The origin of the radionuclide decay along the LOR cannot be determined from the 
detection of the annihilation photons alone.  Therefore, prompt LORs are generally 
plotted in a 2D histogram sorted by distance, r, from the center of the field of view (FOV) 
and angle,  , which will later need to be reconstructed to make an image. This plot is 
generally known as a sinogram since a point source will create a sine wave plot (figure 
2.2 a, b).   
  
Figure 2.2 Simple circle and eclipse a) geometry used to provide examples of b) 
sinogram, c) backprojection, and d) filtered backprojection 
2.1.2 Corrections 
PET is currently the most quantitatively accurate tomographic imaging method for 
determining radionuclide concentraitons in tissue.  However, before PET images can 
provide quantifiable information, several corrections must be applied. First, a correction 
is needed for random events. There are two common random correction methods, singles-
based and delayed random window correction (DRCC).  In the singles-based correction 
method, the randoms are estimated based on the single photon detection rates of the 
detectors using the following relationship; 
18 
 
Equation 2.1 
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where  is the coincidence time window and si and sj are the single photon detectrion rate 
of detectors i and j respectively.  The estimated randoms, Rij, can then be subtracted from 
the prompts for each coincident circuit, ij, to provide an estimate of ture event rates(35).  
However, the singles based correction method requires accurate estimates for the singles 
rate for each detector, which can only be achieved with corrections for detector 
limitations such as deadtime, pulse pile-up, localized efficiency, and energy resolution. 
Inaccurate knowledge of these parameters can lead to bias in the randoms correction. 
The second randoms correction method, DRCC, works by subtraction of delayed 
coincidence events from the original prompt events.  Delayed events are coincidence 
events generated  following a short termporal gap in one of the detector channels, 
generally around 10 ns, which would make it impossible that both photons to have 
originated from the same annihilation event. DRCC does not require corrections for the 
detection problems specified above, but does does result in a lower signal-to-noise ratio 
than the single event method due to the randoms coincidence detection event rate. To 
reduce this noise, some DRCC corrections average, referred to as “smoothing” the 
delayed events across adjacent coincidence LORs prior to subtraction.  This requires the 
delayed events to be transferred and processed prior to performing the correction while 
the non-smoothed DRCC can be completed online as part of the data acquisition process.   
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Scatter events also need to be corrected in order to produce unbiased quantitative 
radionuclide concentration estimates.. Like randoms corrections, there are many types of 
scatter correction methods.  All datasets in this dissertation had a model based scatter 
correction applied.  Model based scatter correction consists of subtracting a predicted 
scatter sinogram from the prompt sinogram following the random correction.  The scatter 
sinogram is created from a model using the attenuation map provided by the CT 
associated with the PET and emission data to predict the events which were generated by 
compton scatter.  These models have been shown to accurately predict scatter inside the 
field of view (FOV), but have difficulty predicting scatter events caused outside the 
FOV(36).  To remove the scatter from outside the FOV, the scatter sinogram is scaled to 
fit the tails of the random corrected prompt sinogram.  Since the tails of the sinogram 
arise from outside the FOV, all tail activity is presumed to be from scatter events, 
assuming the random correction was correct. 
Corrections for attenuation is also needed since not all annihilation photons will reach the 
detectors due to absorption and compton scattering.  To correct for attenuation, most 
modern clinical scanners have an associated CT which can provide attenuation correction 
factors (ACF) created based on the attenuation of CT transmission.  Since CT photons 
have lower energy than annihilation photons, CT attenuation values are scaled to 511 keV 
prior to the correction. ACF can then correct for attenuation through numerical itergration 
for each LOR(37).  
Normalization is additional correction which is made due to the differences in individual 
crystal effeciencies from variations in PMT gains, detector block location and detector 
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gaps. Normalization is completed through a periodic acquisition of an uniform source.  
Since the source is uniform, all LORs would be expected to receive the same photon flux 
and the normalization factor is calculated as,  
Equation 2.2 
 
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, 
where  is the mean coincidence counts across all LOR and Fi and Ai are the 
normalization factor and coincidence counts for the ith LOR(38). 
Deadtime is the final correction used during our PET acquisitions.  Deadtime is the 
period of time after a single event is detected that a new single can not be detected due to 
detector or electronic recovery times.  Deadtime corrections are extremely important 
when there are high count rates, which has not the case with 90Y. 
2.1.3 Reconstruction 
Following corrections, the sinogram has to be reconstructed to create an image. There are 
two general forms of PET image reconstruction algorithms, analytical or iterative. 
Analytical algorithms are closed form solutions for the reconstruction. The most 
commonly used analytical algorithm is filtered back projection (FBP), which is based 
upon Radon transform theory.  In FBP each measured  LOR  is projected back across the 
image space to generate an image. However, if the projections were simplying back 
projected, the low frequency would spread across the background of the image (Figure 
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2.2c).  Therefore, a filter is applied to introduce negative values into the projection, 
suppressing the low frequency smear (Figure 2.2d).   
Iterative algorithms are not closed-form solutions but rather numerical analysis solutions 
for the reconstruction.  Iterative algorithms can reduce the image noise as statistical 
predictions can be included in the reconstruction. The most commonly used iterative 
reconstruction is the expectation maximization (EM) method, which starts with an initial 
estimation or guess of an image, which is then forward projected and compared to the 
measured sinogram projections.  The estimated projection is then backprojected to an 
image where corrections are made for the differences found between the projections and 
the process is then repeated.  As the process is repeated, the reconstruction algorithm 
converges to a final image.   A limitation of iterative reconstruction methods is they are 
computativelly intensive due to the number of iterations it takes to converge.  To speed 
up the process, ordered subset iterations were introduced. This approach works by 
splitting up the entire sinogram into smaller subsets, which can then be iteratively 
reconstructed at a faster speed.    
As more iterations and subsets are completed, the image converges and becomes closer to 
the final image.  However, as the reconstruction becomes closer, image noise also 
increases due to small changes in the data(39).  To reduce this noise, reconstruction may 
need to be stopped before complete convergence is reached or smoothing may need to be 
applied after reconstruction.  Since 90Y PET signal is very small, PET images will contain 
a significant amount of noise.  Therefore, the number of iterations and subsets used in 
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reconstruction, in combination with a filter, are important parameters to consider in 90Y 
PET acquisitions.  
In many scanners today, including the Siemens Biograph 64 TruePoint PET/CT at 
Indiana University Health University Hospital which was used in all our studies, data is 
collected in a 3 dimensional acquisitions.  Therefore, the 3D data needs to either be 
rebinned or more complex algorithms need to be applied to reconstruct 3D sinograms.  
All data in this work was rebinned prior to reconstrcution for both analytical and iterative 
algorithms using Fourier rebinning (FORE) algorithm described by Defrise et al.(40). 
2.2 Materials and Methods 
To validate patient imaging results, images of a Jaszczak cylindrical phantom containing 
cylindrical inserts with an inner diameter of 38 mm filled with 80 ml of known 
concentrations of 90Y-Cl3 solution on a Siemens® Biograph TruePoint PET/CT.  Total 
activity was 1.01 ± 0.1 GBq, calculated by subtracting residual activity measured by a 
Biodex Atomlab 100 dose calibrator from the supplier’s calibration record and corrected 
for decay to the time of imaging.  A 2.5 hour list mode acquisition was collected.   
The acquisition was reconstructed using various reconstruction protocols.  The current 
clinically used algorithm is TrueX, a Siemens® commercial OSEM reconstruction with 
point spread function recovery iterative reconstruction algorithm, at 2 iterations and 14 
subsets (2i14s).  The phantom was therefore reconstructed using TrueX® with various 
iterations and subsets to evaluate their effect.  Additionally, the phantom was analytically 
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reconstructed using DiFT.  Commercial corrections for random, scatter, normalization, 
deadtime, and attenuation were always applied.  
All reconstruction protocols were evaluated in terms of accuracy and minimum 
detectable concentration (MDC).  Quantitative accuracy was determined by comparing 
the observed syringe radionuclide quantity in the phantom images to the true activity. 
Recovery coefficient (RC) was used as the figure of merit to determine quantitative 
accuracy. Measured radionuclide quantities were calculated using a region growing tool 
on CT images to create volumes of interest (VOIs).  Each VOI was expanded 1 pixel 
length (4mm) around its surface using MIMVista® software to ensure all activity in each 
syringe was measured.  
MDC is defined as the smallest activity within a standard volume which can be detected 
at a specific confidence level, generally 95% and can be found using Curie’s equation: 
Equation 2.3 
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where MDCnet is the minimum concentration that can be detected following background 
subtraction and b is the measured standard deviation(41). The gross MDC was then 
determined by adding the measured mean background concentration (Cb), 
Equation 2.4 
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To determine  b, the 2.5 hr acquisition was divided into 10 minute frames to produce 15 
different images for each reconstruction. Concentration from 10 background voxels 
placed at random in the center of the phantom were then measured for each frame.  The 
measured mean and standard deviation across frames was determined for each voxel.  
The image  b was then defined as the mean of these 10 individual voxel standard 
deviations and 

was the mean of all voxel measurements.  
Signal to noise ratio (SNR) was determined for the hottest insert in all reconstructions.  
SNR was found by dividing the average by the standard deviation of the measured insert 
concentration found across the frames. The SNR was then normalized to the clinically 
used 2i14s TrueX reconstruction for comparison.  
2.3 Results and Discussion 
DiFT reconstruction was extremely noisy with an MDC of 3.1 MBq/ml (Figure 2.3).  
Additionally, all insert measurements following DiFT reconstruction had RC less than 
0.9 due to the presence of negative voxel values inside the VOI. DiFT SNR for the 
highest concentration insert was only 73% that found in 2i14s TrueX reconstruction. Due 
to extremely poor 90Y positron signal compared to background noise, DiFT 
reconstruction inability to reduce noise, DiFT is not recommended for use in quantitative 
90Y PET/CT imaging due to its inability to include noise reduction into its reconstruction.  
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Figure 2.3 Phantom image following DiFT reconstruction 
As shown in Figures 2.4 and 2.5, increasing iterations and subsets in the TrueX 
reconstruction showed an increase in the RC as the reconstruction converged (figure 
2.5a). However, MDC was also found to increase with higher iterations and subsets 
(figure 2.5b).  The clinical 2i14s RC was found to be 90.8% for the hottest insert, with an 
MDC of 1.07 MBq/ml. Increasing the clinical 2i14s one iteration only increases the RC 
by 1.3%, while increasing the MDC 18.9%.  Additionally, increasing the subsets to 21 
only increased the RC by 0.6% while increasing the MDC 21.9%.   
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Figure 2.4 Images created using various iterations and subsets in the TrueX 
reconstruction 
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Figure 2.5 Phantom analysis of for a) RC of the highest activity insert, b) phantom MDC, 
and c) SNR normalized to 2i14s for various iteration and subset TrueX iterative 
reconstructions. d) RC of all phantom inserts for various subsets using 2 iterations 
The SNR was highest for 14 subsets.  Additionally, the SNR increased 10% between 1 
and 2 iterations, while increasing only 1.8% going from 2 to 3 iterations (Figure 2.5c).  
Therefore, the recommendation is to continue using the current clinical 2i14s and is used 
for the remainder of the study.  
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Figure 2.5d demonstrates a positive bias at low concentrations.  This positive bias leads 
to an average measurable background concentration of 0.4 ± .1 MBq/ml following 2i14s 
TrueX reconstruction.  The positive bias is discussed further in chapter 4.  
Table 2.1 PET insert 90Y activity measurements for scattered and non-scattered corrected 
datasets following online and smoothed delayed random coincidence correction 
Insert 
Total activity 
(MBq/ml) 
Scattered 
corrected 
Non-scattered 
corrected 
Online Smooth Online Smooth 
1 378.8 348.5 291.7 338.1 323.4 
2 250.4 239.5 182.8 231.8 216.7 
3 221.4 218.7 159.9 206.9 190.9 
4 132.1 144.0 87.6 137.9 127.0 
5 27.9 61.9 11.4 64.5 60.8 
 
Smoothing the random sinogram prior to the random correction significantly changes the 
results from the online random correction (table 2.1). The difference between the two 
images is reduced if the scatter correction is turned off.  Comparison of the scatter 
sinograms shows the sinogram following the smoothed random correction is scaled 
higher than following the online random correction (Figure 2.6). Since the smoothed 
random correction leads to underestimation of all insert measurements, this indicates 
smoothing the randoms prior to subtraction leads to an inadequate scatter correction.  It is 
likely that smoothing the randoms leads to an underestimation of randoms outside the 
FOV, found in the prompt sinogram tail, since the scattered sinogram is scaled higher 
than the online random sinogram.  Further research is needed to determine the cause.  
Due to the underestimation of results, the online random correction was used for the 
remainder of the study.  
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Figure 2.6 Total counts in scatter sinogram projections following online and smooth 
DRCC 
2.4 Conclusion 
This study demonstrates that care should be taken when selecting reconstruction 
protocols for quantitative 90Y PET/CT imaging due to its very low signal-to-noise ratio.  
Closed form reconstruction solutions which are generally desired for quantitative 
analysis, such as DiFT, are not recommended for 90Y imaging due to its inability to 
incorporate noise reduction into the reconstruction. Smoothing the random sinogram 
before the random correction is not recommended due to reduced activity recovery 
believed to be caused by inadequate random correction in the sinogram tails, leading to 
erroneously high scatter correction. For the Siemens® Biograph 64 PET/CT TruePoint 
scanner, the recommended reconstruction protocol was found to be 2i14s TrueX with 
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online random correction based on a balance between MDC limitations, quantitative 
accuracy, and SNR.
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CHAPTER 3. ORIGIN OF 90Y PET SIGNAL AND NOISE 
3.1 Introduction 
Substantial research has demonstrated the feasibility of producing PET images following 
radioembolization. However, few studies  have been performed exploring coincidence 
count rates associated with 90Y PET imaging. Due to the very small internal pair 
production decay branching ratio of 90Y, the PET signal from positron annihalition events 
will be extremely small even while imaging the large doses used in radioembolization 
therapy. A typical therapeutic dosage of 2.4 GBq of  90Y only produces 76481 positrons 
per second, equivelent to the positron production rate of 79 kBq of 18F which is the most 
common PET radioisotope due to its 97% positron emission rate.  This is significantly 
smaller than the hundreds of MBq used for clinical diagnostic PET imaging procedures.    
As discussed in chapter 2, random coincidence counts are a source of noise which need to 
be corrected for when reconstructing PET images.  In clinical PET imaging where the 
positron annihilation or “true” signal is much higher, random coincidences generally arise 
from the detection of two photons from different annihilation events.  The signal from 
these radiopharmeceuticals is enough to dominate the singles rate, making random 
coincidence counts increase roughly proportionally with the square of source activity as 
demonstrated in equation 2.1.  However, the annihilation photon rate  from 90Y will be 
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much lower than for standard PET radionuclides. Therefore, photon sources other than 
annihilation photons dominate the observed single event rate leading to randon to true 
event ratios that are very different than observed with standard PET radionuclides.  This 
study will evaluate  single and coincidents event rates observed when imaging 90Y.   
from sources other than annihilation events will likely have a greater impact on the 
singles rate and therefore effect random events differently. This study will evaluate the 
origin of singles and coincidents events to evaluate the PET signal associated with 90Y 
imaging.   
The first non-annihilation photon source which may lead to random coincidence counts is 
present only in PET systems which use Lutetium (Lu) based scintillators, such as Lu 
Oxyorthosilicate (LSO) or Lu-Yttrium oxyorthosilicate LYSO crystals.  Lu used in these 
crystals contain radioactive iosotope 176Lu  at its natural abundancy of 2.6%. 176Lu decays 
through  - decay, with a mean energy of 420 keV, followed by prompt emission of 
gamma () rays with energy of 307 keV (94%), 202 keV (78%), and 88 keV (15%)(42) 
(figure 3.1). 
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Figure 3.1 Natural Lu-176 decay schematic 
Some of the 176Lu  - particles will contain energies which fall within the energy window 
and will produce single events, and therefore increase random coincidence events.  
Additionally, if two of the photons in the cascade following the  - emission both hit the 
same detector block, they can build up to create a pulse which can fall into the PET 
energy window requirements and create a measured event.  With this hit, prompt 
coincidence event can be made with the hit from the detection of the  - particle. It has 
been shown in the past that both the random and prompt coincidences from 176Lu produce 
count rates significantly lower than the count rates from clinically used activities of 
positron emitting radiopharmaceuticals as long as the PET lower energy threshold is set 
greater than 350 keV(43, 44).  As clinical scanners generally have lower energy 
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thresholds greater than 350 keV, coincidence counts from 176Lu are generally ignored.  
However, since 90Y signal is so low, it is expected 176Lu will lead to substantial 
proportion of the count rate and are explored in this study.   
Another source of non-annihilation photons is Bremsstrahlung produced  by high energy 
  particles emitted in 90Y decay as they travel through tissue.    With a maxiumum   
energy of 2.28 MeV, these bremsstrahlung photons can have energies which meet PET 
energy window requirements, leading to increased single event rates and therefore 
random counts(45).   
Additionally, the bremsstrahlung photons can have energies greater than 1.022 MeV 
which can result in pair production as the photon interacts with matter.  Bremsstrahlung 
pair production rates are expected to be a very small proportion of coincidence counts as 
only a small fraction of bremsstrahlung photons will have enough energy to create a pair 
production event.  This event would then need to occur in a specific geometry to 
complete a coincidence circuit and create a PET coincidence count. This geometry is 
unique as the probablity of photons with energy below 2 MeV interacting with a low Z 
material, such as tissue, is extremely low.  Therefore, the only photon pair production 
which could be registered would be when the pair production occurred in the detectors 
scintilation crystals themselves.   This would lead to an unique detection scenerio as the 
positron which is produced through the pair production would deposit its energy inside 
the crystal.   Therefore, the true event would be counted only if the positron  had energy 
within the PET energy window and one of the annihilation photons was detected in 
another block to complete the coincidence circuit. Therefore, true events produced by 
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bremsstrahlung pair production are expected to be extremely rare but for completeness, 
are still evaluated in this study. 
The purpose of this chapter is to explore the signal and noise associated with 90Y PET 
imaging using both experimental data and Monte Carlo (MC) simulations.  This study 
will evaluate the relationship between random coincidence event rates , 90Y activity 
levels, the proportion of counts which arise from 176Lu present in the detector crystals, 
and bremsstrahulung photons associated with the 90Y  - decay.   
3.2 Materials and Methods 
3.2.1 GATE model Monte Carlo Simulation 
MC simulations are routinely used to computationally model radioactive particle 
interactions with matter in physics problems. MC  uses random number generators to 
model particles interactions with matter based on the statistical probabilities of 
interactions.  There are numerious software packages available which provide particle 
transport MC simulations.  A popular MC software specificatly designed for medical 
applications known as Geant4 Application for Tomographic Emission (GATE)(46), is 
used in this study.  GATE is popular for nuclear medicine applications as its user friendly 
macros are specifically designed for modeling imaging modalities, while being 
incorporated with a much larger and complex MC software package known as 
GEneration ANd Tracking (Geant4)(47).   
36 
 
The GATE model created in this study was for our scanner, the  Siemens Biograph 64 
TruePoint PET/CT to predict the origin of all coincidence counts produced with 90Y 
decay.  This model was comprised of 4 rings in accordance with the Biograph TruePoint 
geometry (Fig 3.2).  Each ring contained 48 detector blocks, which contain 169 Lutetium 
Oxyorthosilicate (LSO) crystals in 13 x 13 arrays.  The individual crystals have a surface 
areas of 4x4 mm2 and depth of 20 mm.  The  system geometry was implemented based on 
private communications with Siemens. A carbon fiber bed, PMT, and lead end shields 
were also included in order to appropriately model photon attenuation and scatter. 
 
Figure 3.2 Gate model displaying crystals, blocks, PMT, gantry table and phantom 
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GATE uses Geant4 physics models to simulate electromagnetic transfer processes, with 
standard and low energy Penelope models being most common for tomography 
simulations.  In this study, the low energy Penelope model was used for Rayleigh 
scattering. Photoelectric, electron ionization, Bremsstrahlung, gamma conversion, and 
compton scattering physics processes were modelled using standard models to minimize 
computational time. Table 3.1 provides the threshold “cuts” which were used for 
secondary particle and radiation production to optimize computational runtime.  
Table 3.1 Particle cuts for GATE simulation model 
Particle Phantom Crystal 
Gamma 10 keV 50 keV 
Electron 0.1 mm 1 cm 
Positron 0.1 mm 1 cm 
 
In addition to geometry, GATE also models the behavior of detector response and signal 
processing through a digitizer module.  This module starts once a detector is hit, which is 
defined as a physical interaction with the models sensitive detector, or crystals in our 
module.  The GATE digitizer module then processes these hits to determine the 
coincidence counts which would be registered by the scanner using a number of digitizer 
macro commands.  The digitizer module parameters used in our model of the Siemens® 
Biograph TruePoint 64 are shown in Table 3.2.   
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Table 3.2 Digitizer module parameters used in the Siemens Biograph TruiPoint 64 
PET/CT GATE model 
Module Name Description User Defined Paramenters 
Adder 
Sums all energy in a single 
crystal into one pulse. 
NA 
Readout 
Combines all pulses from a 
sensitive volume into one 
output pulse. 
Sensitive Volume = Block 
Time Resolution 
Adds time resolution of the 
crystal 
Time Resolution = 500 ps  
Crystal Blurring 
Adds efficiency and blurs 
energy based on crystal 
properties 
Energy Resolution = 15% at 511 
keV  
Crystal Efficiency = 0.9 
Deadtime Adds crystal deadtime 
Time = 136 ns 
Module = paralysable 
Energy Threshold 
Changes pulses into singles 
based on PET energy 
threshold 
Lower Thresholder = 435 keV 
Upholder = 650 keV 
Coincidence Sorter 
Sorts singles into coincidence 
pairs 
Coincidence window = 4.5 ns 
Coincidence offset  = 0 ns 
 
3.2.2 Phantom Validation 
A 10 minute duration scan of the PET phantom described in chapter 2 was acquired once 
a day for 5 consecutive days to produce image data sets with  varying 90Y activites.  
Phantom studies were performed with the MC simulation model in order  to validate the 
models ability to predict prompt and random coincidence count rates.  90Y Geant4 
radionuclide sources set to the concentrations inside the cylidrical inserts were used to 
model the  - decay. As the 90Y internal positron emission is not included in the Geant4 
ion source model, 511 keV back-to-back gamma photons were also included at the 
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3.1867e-5 branching ratio. To mimic the natural radioactivity present in the crystals, a 
176Lu radionuclide source was created confined to the crystal volume was inlcuded in the 
model. The total activity of 176Lu was determined by matching the randoms coincidence 
rate to the cold acquisition.  
3.2.3 Evaluation 
Average relative percent error was calculated using the following equation to establish 
the correspondance between  the GATE model and data measured with the Biograph-64,  
Equation 3.1 
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Where Cs and CA where coincidence count rates from the simulation and phantom 
acquisition, respectivily.  The prompt to random noise ratio (PRR) was calculated by;  
Equation 3.2 
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where P are prompt coincidence counts and R are random coincidence counts.  
Additionally, the prompt coincidence counts were compared from individiual phantom 
cylindrical inserts by comparing the fractional count rates arising from each insert to the 
fraction of the total activity found in each insert.  The standard deviation, as shown in 
figure 3.3, for the fractional activity was determined by variance propogation assuming 
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10% error in each insert activity as described in chapter 2.  All 5 simulations were used to 
determine the simulation sample standard deviation using the standard equation, 
Equation 3.3 
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3.3 Results 
The total background coincidence rate from natural 176Lu was observed to be 1027.3 
coincidences per second (cps) in the cold acquisition.  The majority of these coincidences 
came from random counts, 1020.3 cps, while 7.0 cps were registered as true/scatter 
coincidence counts. A total 176Lu activity of 1.975 MBq confined to the crystal volume 
was used to match this coincidence rate.  The simulated coincidence cout rates for 
true/scatter and random coincidences was 1018 and 4.5 cps, respectively.  
The simulation was able to predict prompt and random coincidence rates for all five 
phantom acquisitions (Table 3.3).  The average relative percent error between the 
simulation and experiemental prompt and random coincidence rates was 3.3±1.7% and 
2.1±1.4%, respectively.   
The random events were found to increase with increasing 90Y activity.  However, this 
increase was found to be approximately proportional to 90Y activity, not the square of  
90Y activity  (Fig. 3.2). The majority of this increase was found to be produced by one 
176Lu and one bremsstrahlung photon being detected in coincidence (Fig 3.2). In the 
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highest activity phantom, only 1% of random events were produced without one photon 
from 176Lu.  A random event rate of only 0.5 cps could be attributed to two separate 
annhilation events from 90Y pair production.  
Table 3.3 Phantom prompt and random coincidence count rates and signal to noise ratios 
for the GATE simulation (sim) and experimental (exp) phantom acquisition 
Day 
90Y 
Activity 
(MBq) 
Exp. 
P 
(CPS)
Sim. 
P 
(CPS)
Exp. R 
(CPS) 
Sim. R 
(CPS) 
Exp. 
PRR 
Sim. 
PRR 
1 1008 1412 1454 1201 1218 0.19 0.18 
2 793 1312 1365 1161 1176 0.16 0.13 
3 610 1220 1290 1106 1156 0.12 0.10 
4 475 1182 1216 1089 1112 0.09 0.08 
5 362 1161 1173 1091 1105 0.06 0.06 
 
 
Figure 3.3 Increase of random coincidence counts are proportionally linearly to 90Y 
activity 
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Figure 3.4 Random coincidence counts originating from LSO, bremsstrahlung (brem), 
and pair production annhiliation (pp) photons single detection hits found using GATE 
simulation of the highest activity 90Y phantom PET acquisition 
Detection of the LSO   decay and cascade photons was found to produce only 3 
additional prompt coincidence counts per second.  Additionally, detection of the 
annihilation photons from high energy bremsstrahlung photons pair production was found 
to only produce 1 prompt coincidence counts per second. Combined, this produced less 
than 2% of all true coincidence counts, in the phantom with the highest activity.  
Figure 3.4 demonstrates that the fraction of true counts from each insert matches within 
one standard deviation the fraction of activity in each insert.  This is even true in the 
lowest activity insert, whose concentration was always below the MDC of 1 MBq/ml as 
described in chapter 2.  
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Figure 3.5 Fractional coincidence counts from inserts compared to proportional activity 
for phantom acquisitions 
3.4 Discussion 
The results of this study demonstrate that GATE can accurately simulate the prompt and 
random count rates of 90Y acquisitions on a Siemen’s Biograph TruePoint 64 PET/CT.  
To the best of my knowledge, this is the first simulation which models 90Y PET signal as 
well as this particular scanner. This simulation illustrates the extremely low prompt 
signal to random noise associated with  90Y imaging on LSO PET scanners, showing that 
even at 1 GBq the PRR is below 0.2.  
In addition to detection of 90Y annihilation photons, GATE predicted only 3 cps of 
additional true coincidence counts in the phantom containing 1 GBq.  As expected, only a 
very small proportion of true coincidence counts were the result of high energy 
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bremsstrahlung pair production, with producing only 1 prompt cps, or 0.6% of all prompt 
counts, in the highest activity phantom acquisition. 
The other non-90Y true event occured from the cascade decay of 176Lu.  Again, this is an 
unlikely occurance since the 176Lu  - energy would have to create one single, and the pile 
up of two of the cascade gamma’s would have to create the other due to energy window 
requirements.  This appeared to occur at a rate of approximately 2 coincidences per 
second regardless of the activity inside the phantom. This equates to about 1% of all 
prompt coincidences observed with 1 GBq of  90Y.   
The LORs created by the LSO and bremsstrahlung pair production would not necessary 
line up with the source location since these true events did not originate from the 90Y 
source.  Therefore, these events would produce background noise that would be 
distributed throughout the image.  However, since these events only contribute to a very 
small fraction of true events and therefore would not generate significant background 
noise.   
In addition to the true events, the origin of the random events was also analyzed in this 
study. Due to the extremely low positron signal of 90Y, the majority of the random counts 
are due to the intrensic 176Lu in the LSO crystals.  The model showed there was no 
increase in randoms counts observed from detection of two photons from different 
annihilation events as is generally the case with diagnostic PET radiopharmeceuticals.  
However, randoms increase with 90Y activity, mostly due to the presence of 
bremsstrahlung photons. The majority of this increase was due to the detection of one 
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bremsstrahlung photon and one 176Lu.  Therefore, detectors without Lu based crystals 
would be expected to have better counting statistics for 90Y imaging.  
Finally, the fractional count rates from the phantom inserts in the simulation were found 
to line up with the fraction activity from the phantom acqusition. This demonstrates that 
the MDC of 1 MBq found in chapter 2 and described again in chapter 4 for this 
reconstruction is not due to the detection of the positron signal but is due to the large 
noise presense.  Therefore, an accurate correction for random events is essential for 90Y 
imaging.  
3.5 Conclusion 
The study demonstrated the feasibility of using a MC simulation created in GATE can 
accurately simulate the count rates associated with 90Y acquisitions on a Siemen’s 
Biograph TruePoint 64 PET/CT.  Using this simulation, these count rates can be 
evaluated to demonstrate the extremely poor prompt signal to random noise associated 
with 90Y due to the large presence of random coincidence counts associated with 
bremsstrhalung and 176Lu photons.  Therefore, the accurate corrections for random events 
areshown to be essential for 90Y imaging. 
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CHAPTER 4. THE IMPACT OF 90Y PET IMAGE RECONSTRUCTION BIAS ON 
PATIENT DOSIMETRY FOLLOWING RADIOEMBOLIZATION  
4.1 Introduction 
As shown in the previous chapters, 90Y is not an ideal PET radionuclide due to its low 
SNR, producing an image acquisition scenario with high random to true coincidence rate 
ratios. In this type of scenario, the DRCC which corrects for random coincidence counts 
can lead to negative sinogram values as a result of the stochastic nature of radionuclide 
decay.  These negative values are often truncated in commercial software packages prior 
to reconstruction to provide concavity in iterative reconstruction algorithms. This 
sinogram element truncation is known to cause positive bias(48-50).   The purpose of the 
study described in this chapter was to evaluate the magnitude of this bias in 90Y PET/CT 
images reconstructed following this truncation and to assess the feasibility of utilizing 
90Y PET/CT images to estimate 90Y dosimetry in tumor and treated lobe parenchymal 
volumes following radioembolization. 
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4.2 Materials and Methods 
4.2.1 Image Acquisition and Reconstruction 
90Y PET/CT patient studies acquired approximately 1 hour after right or left hepatic 
artery TheraSphere® injection at Indiana University hospital in Indianapolis, IN between 
February 2011 to January 2013 were analyzed retrospectively.   The Indiana University 
institutional review board approved this retrospective study and the requirement to obtain 
informed consent was waived.  
Data acquisition durations were 10 minutes per bed position on the Siemens PET/CT 
Biograph® 64 TrueD and had vendor supplied DRCC, decay, scatter, normalization, and 
attenuation corrections applied. Patient images were acquired using Siemens' net 
acquisition mode, which corrects for randoms real time and reconstructed using Siemens’ 
iterative reconstruction algorithm with point spread function spatial recovery, TrueX®, 
which truncates negative ray-sum values in the sinogram prior to image 
reconstruction(13).  Images were reconstructed with 2 iterations, 14 subsets which results 
from chapter 2 demonstrated provided the best compromise between accuracy and noise. 
PET DICOM image arrays were post processed in IDL (Interactive Data Language, 
Research Systems Inc., Boulder, CO, USA) to apply the 90Y positron branching ratio and 
proper decay correction for quantification.  
The cylindrical phantom acquisitions collected over 5 days described in chapters 2 and 3 
were used to validate patient image results. In addition to the net acquisition mode, 
phantom data were also collected using a prompt/random acquisition mode.  The 
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prompt/random acquisition mode saves both prompt and delayed sinograms, enabling 
averaging or smoothing of the delayed sinogram bin values prior to DRCC.  Given the 
delayed sinogram provides an estimate of random coincidence rates, smoothing the 
sinogram reduces variance introduced during the DRCC(35, 51).  In addition to TrueX® 
reconstruction, phantom data was also reconstructed using DiFT with and without 
sinogram truncation to evaluate the effect of sinogram truncation.  Quantitative accuracy 
and MDC were found as described above in section 2.2.  
4.2.2 Image Bias 
Image bias was determined by comparing the administered quantity of 90Y to the 
measured radionuclide quantity across the image field of view (FOV).  For the patient 
studies the administered 90Y quantity was defined as injected activity, minus the 
estimated lung shunt fraction (LSF) for image volumes that excluded the majority of the 
lungs. Manufacturer calibration records were used to determine the injected 90Y activity 
for each patient, corrected for decay and residual activity. A 10% uncertainty was 
assumed for the assay of 90Y quantities.   The LSF was determined by a pre-treatment 
SPECT scan of 99mTc-MAA injected during the patients planning arteriogram performed 
approximately 2 weeks before radioembolization. PET images with 2 bed positions 
contained a majority of the lung in the FOV, and therefore no subtraction was made to 
remove the lung activity in defining the administered FOV quantity.  The administered 
whole liver quantity was corrected for the LSF in all studies. 
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For the phantom studies, the total radionuclide quantity measured across the entire PET 
FOV was compared to the total syringe activity. Using IDL software, net acquisition 
uncorrected sinogram values were binned to create a histogram to demonstrate the 
distribution of positive and negative values observed following real time DRCC.  
Prompt, random, and true events were recorded from multiple acquisitions of 90Y and 
fluorine-18 (18F) point sources to evaluate the impact of bremsstrahlung photons on 
random coincidence count rates. Three acquisitions of 90Y activities of 3.8, 1.7, and 0.2 
GBq, contained in original TheraSphere® vials, were collected. Additionally, 4 
acquisitions were collected every half hour with a vial filled with 18F.  The 18F activity for 
the first acquisition was 0.13 MBq, decay corrected from an initial activity of 8.5 MBq as 
determined by the dose calibrator.  An additional acquisition was collected with no 
activity present to determine the background count rate.  
4.2.3 Absorbed Dose Maps 
PET radionuclide concentration images were converted to dose maps in accordance with 
MIRD 17(52). Voxel S values were constructed for the PET voxel size (4.07 x 4.07 x 3 
mm) using Monte Carlo radiation transport code MCNPx,(53) using 108 starting  - 
particles and a cutoff energy of 1 keV.   Dose maps were generated by convolving the 
voxel S values with PET DICOM cumulative activity arrays in IDL.  
Phantom syringe VOI dose measurements were used to validate dose map results through 
comparison with expected dose values using the clinical dosimetry equation: 
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Equation 4.1 
  
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where A is activity in GBq, M is mass in Kg assuming liver tissue density, and D is dose 
in Gy(5).  
4.2.4 Patient Dosimetry 
Figure 4.1 illustrates radiologist defined contours of the lesion (blue) and treated lobe 
(green) created on the PET associated CT images used to determine radionuclide 
quantities and tissue volumes for all patient studies.  Necrotic volumes (red) were also 
contoured to separate from viable lesion volumes.   
Only tumors greater than 1 cm were included in the study.  Studies with indiscernible 
tumor boundaries were excluded.  In studies with large necrotic centers, the tumors were 
contoured to differentiate between viable and non-viable tumor volumes. Healthy normal 
tissue parenchymal contours were constructed by removing tumor volumes from the 
treated lobe contours. Mean tumor doses were estimated by placing the contours on the 
PET dose maps. 
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Figure 4.1 Patient PET/CT images following a) 3.6 and b) 3.2 GBq uni-lobar 90Y 
radioembolization demonstrating radionuclide quantity observed throughout the field of 
view 
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Figure 4.1 illustrates radiologist defined contours of the lesion (blue) and treated lobe 
(green) created on the PET associated CT images used to determine radionuclide 
quantities and tissue volumes for all patient studies.  Necrotic volumes (red) were also 
contoured to separate from viable lesion volumes.   
Only tumors greater than 1 cm were included in the study.  Studies with indiscernible 
tumor boundaries were excluded.  In studies with large necrotic centers, the tumors were 
contoured to differentiate between viable and non-viable tumor volumes. Healthy normal 
tissue parenchymal contours were constructed by removing tumor volumes from the 
treated lobe contours. Mean tumor doses were estimated by placing the contours on the 
PET dose maps. 
Measured quantities are expected to be overestimated in voxels with concentration below 
the MDC. The maximum potential activity from bias can be quantified assuming all 
activity in voxels below the MDC is from bias. MIMVista® upper bound threshold tool 
set to the MDC was used to determine this maximum bias activity for each VOI. 
Maximum bias activity can be converted to maximum dose bias by separating the activity 
from measurements above and below the MDC in the clinical dosimetry equation,   
Equation 4.2 
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In this equation,  

represents the activity measured above the MDC,  

 is activity 
measured below the MDC, and M is the whole volume mass. The second term, with the 
activity measured below the MDC, represents the potential dose bias.  
4.2.5 Statistical Analysis 
Data is expressed as mean ± standard deviation.  Phantom VOIs with concentration above 
and below the MDC quantitative accuracy measurements are compared with the 
nonparametric Wilcoxon rank sum test since the continuous measurements were not 
normally distributed.  
4.3 Results 
4.3.1 Image Reconstruction Bias in Patient Acquisitions 
Sixty-five (65) PET/CT acquisitions following right (n=48) and left (n=17) hepatic artery 
radioembolization from 59 patients were included in the analysis, with 16 and 49 having 
1 and 2 bed positions, respectively. The mean injected activity was 2.6 GBq, with a range 
of 0.7 to 5.7 GBq. The mean LSF was 5.3 ± 2.6% and 7.6 ± 4.0% for 1 and 2 bed 
positions, respectively. Diffuse background activity was observed in all patient PET 
images (Figure 4.1).  Total image FOV measured radionuclide quantities exceeded the 
administered radionuclide quantity by an average of 8.4 and 13.5 GBq for 1 and 2 bed 
positions, respectively when using TrueX® following net acquisition (Figure 4.2). The 
mean measured quantity in whole liver VOIs was 0.6 ± 0.6 GBq greater than expected.  
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Figure 4.2 Excess FOV activity observed in patient PET/CT images following net 
acquisitions reconstructed using TrueX® 
4.3.2 Phantom Image Reconstruction Bias 
Bremsstrahlung photons increased the 90Y random coincidence event rates compared to 
18F for equivalent positron emission rates, while true plus scatter count rates were found 
to be similar (Figure 4.3). At 3.8 GBq, 90Y provided a 3.06 fold increase in random 
events compared to background coincidence rates observed with no activity present.  
However, interpolation of the 18F random event rate results showed 18F at the same 
positron emission rate of 121.5 k-positrons (0.13 MBq of 18F) only produced random 
events at 1.03 times background.  
55 
 
 
Figure 4.3 Coincidence count rates for 18F and 90Y point source PET acquisitions 
A histogram of detected highest activity phantom ray-sum values, following net 
acquisition, demonstrated 46.8% of non-zero values were negative (Figure 4.4). Phantom 
net acquisition images with real time DRCC subtraction had radionuclide quantities 
measured across the FOV that exceeded the total radionuclide quantity placed in the 
syringes, with percent errors in the range of 273 to 747% observed during the first five 
days of imaging (Table 4.1, Figure 4.5A).  The range dropped to -0.6 to 26% when the 
delayed window was smoothed with the prompt/random acquisition, with the highest 3 
activity images having less than 10% error (Figure 4.5B). 
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Figure 4.4 Histogram of sinogram ray-bin values following phantom acquisition of online 
DRCC subtraction 
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Figure 4.5 Reconstructed images from a) net and b) prompt/random acquisitions of the 
phantom illustrating decrease of background diffuse bias following random smoothing 
prior to DRCC in the prompt/random acquisition model 
Additionally, positive bias was not observed in any images following net acquisition 
using DiFT reconstruction.  Positive bias was observed following DiFT reconstruction 
when the net acquisition sinogram was truncated prior to reconstruction. 
Table 4.1 Total phantom FOV calculated activity following various reconstructions and 
acquisitions 
Day 
True 
Activit
y 
(MBq) 
TrueX,  
Net Acquisition 
(MBq) 
[Percent Error (%)] 
TrueX, 
Prompt/Random 
Acquisition (MBq) 
[Percent Error (%)] 
DiFT, Net 
Acquisition (MBq) 
[Percent Error (%)] 
 
Truncated DiFT, 
 Net Acquisition 
(MBq) 
[Percent Error (%)] 
1 1008 3755 [273] 1002[-0.6] 800 [-21]  3250 [222] 
2 793 3562 [349] 819 [3.3] 616 [-22] 3135 [295] 
3 610  3282 [438] 628 [3.0] 446 [-27]  2935 [381] 
4 475 3140 [561] 529 [11] 318 [-33]  2777 [485] 
5 362 3067 [747] 454 [25] 244 [-33]  2752 [660] 
13 34.7  2596 [7381] 147 [324]  -46 [-233]  2362 [6707] 
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4.3.3 Quantitative Accuracy 
The 90Y MDC for the net acquisition using the TrueX reconstruction was found to be 1 
MBq/ml.   Quantity and dose measurements from the 16 syringes containing activity 
above the MDC matched expected values within 10% (Figure 4.6, Table 4.2). VOI 
measurements in the 9 syringes with concentrations below the MDC were higher than 
expected.  The positive bias observed in the syringe VOIs with concentrations below 
the MDC produced absolute errors that were greater than the absolute errors observed for 
VOI measurements in syringes with concentrations above the MDC (p<0.0003).   
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Figure 4.6 Phantom insert VOI measurement a) accuracy and b) percent error for images 
reconstructed using TrueX® following net acquisition
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Table 4.2 Phantom image activity and dose estimated from TrueX® reconstruction of 
data collected using the net acquisition mode 
Syringe 
Concentration 
(MBq/ml) 
Day/ 
Syringe 
True 
Activity 
(MBq) 
VOI 
Activity 
(MBq) 
Expected 
Dose 
(Gy) 
Calculated 
Dose 
(Gy) 
Dose 
Percent 
Error 
(%) 
4.72 1/1 378 347 147 135 -8.4 
3.71 2/1 297 268 113 102 -9.9 
3.12 1/2 250 230 99 91 -8.1 
2.86 3/1 229 217 88 86 -2.3 
2.76 1/3 221 208 85 80 -3.2 
2.45 2/2 196 185 74 70 -6.1 
2.22 4/1 178 181 72 71 -0.8 
2.17 2/3 174 164 66 62 -6.0 
1.89 3/2 151 150 59 60 1.9 
1.69 5/1 136 137 57 57 1.0 
1.67 3/3 134 138 51 54 6.5 
1.65 1/4 132 144 51 56 9.4 
1.47 4/2 118 112 49 49 0.9 
1.30 4/3 104 112 41 43 4.0 
1.30 2/4 104 107 39 41 3.2 
1.12 5/2 90 97 38 41 8.3 
0.99 3/4 80 96 31 39 24.8 
0.99 5/3 79 92 32 37 16.5 
0.78 4/4 62 86 24 34 38.7 
0.59 5/4 47 69 19 28 45.8 
0.35 1/5 28 59 11 24 113.1 
0.27 2/5 22 52 9.1 22 138.5 
0.21 3/5 17 49 6.6 20 206.9 
0.16 4/5 13 45 5.4 19 244.4 
0.12 5/5 10 41 4.2 17 317.9 
 
4.3.4 Patient Results 
From the 65 studies, the treated lobe concentration based on expected liver activity 
assuming uniform distribution was greater than the MDC (range 1.03 – 3.64 MBq/ml).  
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However, visual observation confirmed 90Y was heterogeneously distributed, resulting in 
an average treated lobe volume below the MDC of 277.4 ± 204.1 ml, with a range of 25.9 
to 1353.7 ml.  Due to increased uptake in the tumor, the majority of this volume was 
found in the parenchyma with an average of 247.8 ± 149.0 ml, corresponding to an 
average of 27.3 ± 16.9% of the total parenchyma (Figure 4.7A).  The mean total quantity 
measured in the treated parenchyma volume with 90Y concentrations below the MDC was 
170.1 ± 99.4 MBq. This resulted in a mean potential bias of 8.9 ± 4.9 Gy, with 42% 
(27/65) of the studies having potential dose bias larger than 10% the uniform 
parenchymal dose (Figure 4.7B).   
The volume below the MDC in the 115 identified tumors was 16.7 ± 75.8 ml, 
corresponding to 12.2 ± 23.1% of lesion volume, resulting in an average total measured 
quantity of 15.8 ± 55.3 MBq. This resulted in a mean potential bias of 3.3 ± 6.4 Gy, with 
only 9% (10/115) of the studies having potential dose bias larger than 10% the uniform 
lesion dose, all of which had poor (Figure 4.7C). The 10 studies with greater than 10% 
bias all showed poor preferential 90Y deposition with calculated uniform dose of less than 
100 Gy. 
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Figure 4.7 Parenchyma and lesion contours a) fractional treated lobe volume with 
measured concentration below the MDC and the associated potential overestimation in 
dose due to potential bias from measured activity in these volumes for the b) parenchyma 
and c) lesions 
4.4 Discussion 
A large positive bias in the total radionuclide quantity in patient 90Y PET/CT images was 
observed when negative sinogram values were truncated prior to iterative reconstruction. 
Based on the phantom study, the positive bias was found to be restricted to regions where 
90Y concentrations fall below the MDC.   The study demonstrated that 90Y PET/CT 
measured radionuclide concentration is quantitatively accurate, even in the presence of 
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significant positive bias within the image volume, in areas found to contain 90Y 
concentrations above the MDC. 
In the setting of very low coincidence detection rates and high single event rates (as 
observed in our 90Y PET studies) a large number of the sinogram elements are negative 
following online DRCC due to the stochastic nature of the random coincidence events 
detected in both the prompt and delayed coincidence windows.   Truncation of negative 
values leaves only the positive values of the background noise distribution in the 
sinogram.   Reconstruction of sinograms in which negative values have been truncated 
artificially generates radionuclide concentrations in regions of the image that have very 
low radionuclide concentrations while having minimal impact on the reconstructed value 
in regions of the image with high radionuclide concentrations.   Our phantom studies with 
and without sinogram truncation when using the DIFT reconstruction algorithm provide a 
nice demonstration of the impact of truncation in the setting of low coincidence rate and 
high single event rate PET studies.   Our study also demonstrated that smoothing the 
delay window random coincidence rates prior to subtraction reduced the observed bias.  
This type of positive bias is well-documented for PET images reconstructed using 
iterative algorithms with truncated sinograms in the setting of low signal to noise 
ratios(33, 34, 36). 
Past studies have suggested that at low signal, natural radioactive decay of 176Lu, found in 
LSO PET crystals, can cause the majority of the random events leading to the positive 
bias(54). However, the experimental findings from the 90Y point source study showed an 
increase in random coincidences for the 90Y source as compared to background or 
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equivalent rate of positron emission from an 18F source. As shown in chapter 3, this 
increase is due to bremsstrahlung photons produced by the 90Y 2.28 MeV maximum 
energy  -particle. Truncation of negative sinogram values produced by the correction for 
these random events creates a mean excess of 8.4 GBq across the FOV for a 1 bed 
position study.  In comparison, the 1-bed position study of the cold phantom produced an 
excess of 2.6 GBq.  Therefore, the biased background signal observed in regions below 
the MDC is due to both bremsstrahlung and natural radioactivity in LSO crystals.   
Even with the large positive bias observed when quantifying the radionuclide levels 
throughout the imaging FOV, the phantom study demonstrated quantitative accuracy for 
concentrations above the MDC, confirming previous literature findings that 90Y PET 
images are accurate at high concentrations(28, 54).   Through use of voxel MIRD 
methodology, these images also provided accurate dose results for each of these VOIs. 
As expected, bias was observed in VOIs with concentrations less than the MDC, resulting 
in an overestimation of both radionuclide concentration and radiation dose.   
Overestimation of the quantity of 90Y in the liver volume was evident in all 65 patient 
studies, even when considering a 10% uncertainty in the original 90Y assay.  Positive bias 
is expected to have influenced dose results for all patients in this study due to areas with 
concentration below the MDC of 1 MBq. However, due to preferential uptake of 90Y 
microspheres in tumors, the majority of tumors had a very small volume with 
concentrations below the MDC. This favorably results in minimal positive bias within the 
tumor volume.  Thus the potential for error in 90Y concentration estimates from the bias 
in most tumors was found to be relatively small. Ninety one percent (105/115) of 
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identified tumors had a potential bias of less than 10 Gy. The 10 tumors which had a 
potential bias greater than 10 Gy were found to all have calculated doses less than 100 Gy 
due to low 90Y deposition. In these 10 tumors, the calculated dose is still known to be less 
than 100 Gy since the bias is positive. 
Unfortunately, the non-uniform distribution resulted in large portion of the parenchymal 
volume to be below the MDC. This resulted in an average potential bias of 8.9 Gy, with 
40% (26/65) of studies having a potential bias greater than 10 Gy due to the image 
reconstruction bias.   This observation demonstrates that great care must be taken when 
trying to assess radiation dose to normal liver parenchyma based upon 90Y PET images 
when using reconstruction algorithms that employ truncation of negative sinogram 
values.    
4.5 Conclusions 
Due to low positron signal compared to noise from LSO and bremsstrahlung photons, a 
large number of sinogram ray-sum values are negative following DRCC subtraction, 
leading to position bias when truncated in iterative reconstruction algorithms.  Even in 
the presence of this positive bias, quantitative accuracy was good in areas where the 
concentration is above the MDC, enabling accurate estimation of 90Y PET/CT tumor 
dosimetry following radioembolization. A large positive bias was observed in regions 
with low 90Y concentrations, such as found in large areas of the parenchyma in many 
studies, when using sinogram truncation with iterative reconstruction.  Therefore, care 
must be taken in the selection of reconstruction algorithm for estimation of radionuclide 
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concentration and dosimetry in low uptake regions of the image such as the liver 
parenchyma.  
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CHAPTER 5. VERIFICATION OF 90Y PET DOSIMETRY USING POLYMER GEL 
DOSIMETRY  
5.1 Introduction 
5.1.1 Background 
90Y microsphere distribution is not uniform across the treated liver lobe following 
radioembolization.  Consequently, the treatment dose distribution is not uniform.  
Previous studies designed to validate voxel-based dose maps generated using PET or 
SPECT imaging methods used uniform phantoms with homogeneous distributions of 90Y.  
To the best of our knowledge, no evaluation has been conducted verifying 90Y dose maps 
using a heterogeneous validation method.    
In external beam radiotherapy polymer gels(55-57) have been used to verify 
heterogeneous dose distributions.  In addition, polymer gels have been proposed as a 
method for quality control of dosimetry following SPECT imaging of Iodine-131 targeted 
radionuclide therapies(58).  In this study, we propose using polymer gel dosimetry to 
independently verify heterogeneous dose maps produced using 90Y PET/CT images.   
5.1.2 Polymer Gel Dosimetry 
Polymer gels designed as dosimeters are manufactured using radiation sensitive 
monomers which polymerize upon irradiation in proportion to absorbed dose. These gels 
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can then be evaluated in 3 dimensions (3D) by measuring the amount of polymerization. 
Several imaging techniques including CT, optical-CT, MRI, and ultrasound can be used 
to read the gel dosimeters.  
A known limitation of polymer gel dosimeters is that they require extremely low oxygen 
concentration, less than 0.01 mg g-1, because oxygen inhibits the radiation induced 
polymerization through peroxide formation(59).  Therefore, the fabrication and use of 
these gels had to be completed in glove boxes to avoid oxygen contamination.  In 2001, 
Fong et al. proposed Methacrylic and Ascorbic acid in Gelatin Initiated by Copper 
(MAGIC) polymer gel, which uses ascorbic acid mixed with copper(II) complex to 
utilize the oxygen molecules  to support, rather than inhibit, polymerization(59). This 
enables fabrication and use of gel dosimeters in normal room air conditions. 
In this study, MRI is used to determine the amount which the gel is polymerized from 
irradiation.  MRI can indirectly determine the gels exposure by measuring the spin-spin 
relaxation rate, R2, which increases as the irradiation polymerizes the gel, reducing the 
mobility of gel protons(55-57).  Unlike conventional clinical T2 weighted images, R2 (R2 
= 1/T2) values were used to measure polymerization as R2 values filter out image 
inhomogeneity due to inhomogeneous radio-frequency fields ( 1) and external magnetic 
field ( 1)(59).  
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5.2 Materials and Methods 
5.2.1 Polymer Gel Fabrication 
MAGIC gel, as described by Fong et al. with 9% methacrylic acid concentration, was 
used in this study(60). The phantom, a polyethylene cylindrical container, was filled 568 
ml of gel and placed into a refrigerator to allow the gel to cool but not completely set.  
Five hundred and fifty (550) ± 55 MBq in 10 ml of 90YCl3 solution was slowly injected 
while stirring using a long needle to create a heterogeneous distribution.  The phantom 
was sealed and gently shook to provide for additional mixing.   
The change in polymerization, and therefore R2, upon irradiation is based on the chemical 
composition of the gel. Therefore, the correlation between dose and R2 values is 
established using calibration procedures.  The calibration performed in this study used 7 
glass vials filled with 20 ml of gel and varying 90Y activity (95.8 – 4.4 MBq).  These 
calibration vials were sealed and vigorously shaken in order to achieve uniform 
concentrations within each vial.  The vials were then placed inside a large cylindrical 
water phantom for imaging.   
Standard MIRD methods were used to determine the absorbed dose to each calibration 
vial(61): 
Equation 5.1 
  




, 
70 
 
where   is cumulative activity at the time of imaging, n is the number of particles per 
decay, E is the average particle energy,  is the absorbed fraction, and m is the mass of 
the gel.  Cumulative activity was determined based on the time 90Y had to decay in the 
gel prior to the MR scan using the equation:  
Equation 5.2 
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with initial activity,   

, determined via assay in a Biodex Atomlab 100 dose calibrator.  
A 10% uncertainty in the activity measurement was again assumed as described in 
chapter 4. 
Monte Carlo transportation code MCNPx was used to determine the absorbed 
fraction(62). The 90Y electron energy spectrum provided in the Nuclear Regulatory 
Commission radiological toolbox was utilized(63). The electron starting position was 
chosen at random inside a cylindrical geometry modeled to match the calibration vials 
dimensions. Energy deposition throughout the vial was tallied. The MAGIC gel specific 
cross-section data was created using the relative elemental weight fractions and density as 
provided by Fong et al(60).  Additionally, the dose was based on the cumulative activity 
decayed at the time of the phantom MR acquisition, and not based on decay over infinity 
as used when calculating patient dose maps.  
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5.2.2 Imaging Techniques 
MR imaging was completed approximately 13 and 18 hours after manufacturing on a 
Siemens MAGNETOM TIM trio 3T scanner (Siemens Healthcare Molecular Imaging, 
Hoffman Estates, IL, USA), with a 12-echo multiple spin-echo pulse sequence (TR = 
5000 ms, TE = 10, 20, …, 110, 120 ms).  The calibration vials and phantom were 
centered inside a standard head coil. The calibration images had in-plane pixel size of 0.8 
X 0.8 mm2 with a slice thickness of 10 mm.  The phantom images had in-plane pixel size 
of 2 x 2 mm2.  These images were later resized using bicubic interpolation in ImageJ to 
match the 4 x 4 mm2 pixel size of the PET images. The phantom images had a slice 
thickness of 6 mm.   
Pixel T2 values were derived using Siemens Syngo MR B17 commercially available 
workstation.  The reciprocal of the T2 images were inverted in a routine written in IDL 
(Interactive Data Language, Research Systems Inc., Boulder, CO, USA) to produce a 
relaxation rate (R2) map.  Circular regions of interest containing approximately 320 
pixels were drawn over the center of the calibration vials to determine the R2 values for 
the vials for use in the calibration curve with absorbed dose.   
The PET/CT acquisitions were collected in a similar manner as described in previous 
chapters, with 10 minute acquisitions corrected for randoms, decay, attenuation, and 
normalization and a 5 mm Gaussian filter.  Again, acquired data was reconstructed using 
Siemen’s iterative reconstruction algorithm TrueX® with 2 iterations, 14 subsets.  As 
stated in chapter 2, this algorithm includes point spread function spatial recovery which 
reduces the reconstruction point spread function (PSF). PET DICOM image arrays were 
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post processed in IDL to correct for the 90Y positron branching ratio and to apply the 
proper decay corrections. PET images were converted to dose maps similar to the method 
described in chapter 4.  However, a unique S-kernel was used for the dose conversion 
specific to the MAGIC gel, using the chemical composition and density of the MAGIC 
gel in place of liver tissue’s values. Additionally, the dose was based on the cumulative 
activity decayed at the time of the phantom MR acquisition, and not based on decay over 
infinity as described for patient dose maps.   
5.2.3 Dose Comparison 
MIMVista® software was used to visually register MR and CT phantom images, 
allowing for fusion of the MR and PET images. A volume of interest (VOI) was 
generated over the entire phantom using the whole body tool over the CT image to 
evaluate average dose found throughout the whole phantom. The PSF in the PET image 
was measured from a 10 minute acquisition of a 90Y point source (<0.1 mL) placed in the 
middle of the PET field of view. The acquisition was reconstructed and corrected using 
the same method as the phantom. The MR dose map was convolved with the PET PSF to 
allow comparison of similar spatial resolution images.  
Sixty (60) voxels located inside the VOI were chosen at random on the CT image 
associated with the PET to compare the dose maps voxel by voxel. Dose volume 
histograms (DVH) were created with bin sizes of 1 Gy for the VOI. Quantitative gamma 
analysis was performed to evaluate DVH agreement as described by Ebert et al(64). 
Varying volume-difference ( VR) and dose-to-agreement ( DR) criterion were evaluated 
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with gamma ( ) < 1 indicating agreement.  PET dose map was used as the reference 
image for both MRI and MRI convolved with PSF comparisons.  
5.2.4 Statistical Analysis 
Calibration vial R2 values were plotted against calculated absorbed dose and fit using a 
simple linear regression. The standard deviation of the R2 values was determined for each 
calibration vial ROI.  Fractional uncertainty in the calibration dose was determined using 
the method described by Gear et al (65). The standard deviation observed for uniform 
dose values was recorded off the MIMvista VOI.  
5.3 Results 
The calibration vial dose response curve was well described by a linear function (r2 = 
0.966) with a slope and intercept of 0.86 ± 0.040 and -0.038 ± 0.99 with R2 (Figure 5.1).  
The average uncertainty in dose based on linear regression was 2.5 Gy.  The 
corresponding pixel-to-pixel standard deviation in R2 values was 0.75 s-1.  
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Figure 5.1 Calibration dose-response curve of MAGIC gel vials.  The individaual data 
points represent the R2 values with horizontal error bars representing pixel-to-pixel 
standard deviations and vertical error bars representing fractional uncertainty based on 
mass and activity. The solid line is the fit to the measured data.   
The  mean absorbed dose to the whole phantom was 5.3 ± 1.8 Gy for the PET based 
dosimetry and 5.3  ± 1 Gy for the MRI gel-based dosimetry.  Both measurements were 
within one standard deviation of the calculated absorbed dose of 5.8 Gy with an 
uncertainty of 0.58 Gy. 
Table 5.1 Full-width half-maximum (FWHM) of PET point spread function. 
Dimension FWHM (mm) 
x 6.0 
y 6.1 
z 7.3 
 
Coronal slices of the dose maps demonstrate similar dose distribution throughout MR and 
PET images (Figure 5.2a, b).  However, the MRI dose map demonstrates higher dose 
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gradient than the PET map due to the superior spatial resolution in the MRI image.  The 
measured full width half maximum values of the PET PSF are displayed in table 5.1.  
Convolving the MRI dose map with these PSF values results in a resolution similar to 
that found in the PET image (Figure 5.2c).     
 
Figure 5.2 Coronal slices of phantom dose maps from a) PET, b) MRI, and c) MRI-PSF 
with a window of 0 to 30 and a level of 15 Gy. 
Voxel-by-voxel comparison demonstrates the PET dose map generally found lower dose 
values than the MRI due to the poorer spatial resolution of the PET image, resulting in 
the apparent spreading of activity (Figure 5.3a).  However, the MRI convolution with the 
PET PSF resulted in a linear, but nosy, relationship between dose values with a slope of 
0.97 between the PET and MRI-PSF dose maps (Figure 5.3b).  The noise found in the 
image presented in chapter 2 can clearly be seen in this comparison.  
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Figure 5.3Voxel-by-voxel comparison of the PET image with the a) original MR dose 
map and b) MR dose map convolved with the PET PSF 
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Figure 5.4DVH for PET and a) MRI and b) MRI-PSF dose maps from whole phantom 
VOI shrunk 1 cm to avoid boundary influence.  Gamma ( ) value from 3% and 5% dose 
and volume acceptance criteria are as shown. 
Comparison of DVH curves found poor agreement (  > 1) between the original MRI and 
PET dosimetry methods (table 5.2).  The average  -value was 2.5 at 1% for both  VR and 
 DR criterion (figure 5.4a).   Better agreement is reached once the MRI is convolved with 
the PET PSF, with an average -value of 0.9 at 1%  VR and  DR criterion (table 2, figure 
5.4b).  
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Table 5.2 Percent DVH bins with agreement (  < 1) for varying dose and volume 
agreement criterion 
 DR/ VR 
PET versus MRI PET versus MRI-PSF 
1% 3% 5% 10% 1% 3% 5% 10% 
1% 
3% 
42% 67% 76% 95% 61% 100% 100% 100% 
44% 68% 83% 98% 71% 100% 100% 100% 
5% 50% 77% 97% 98% 88% 100% 100% 100% 
10% 58% 95% 97% 98% 88% 100% 100% 100% 
 
5.4 Discussion 
This study demonstrates polymer gel dosimetry is a feasible technique to provide 90Y 
dosimetry using MRI.  With simple linear regression, R2 measurements were able to 
predict the phantom’s mean absorbed dose within the 10% uncertainty in total activity.  
This is similar to the accuracy found in uniform phantom measurements presented in 
chapters 2 and 4.  
Unlike the situation when using the uniform concentration phantom, polymer gels enable 
the use of high spatial resolution imaging such as MRI.  High spatial resolution dose 
maps in turn enable an evaluation of the effect of spatial resolution of the imaging system 
(acquisition and reconstruction techniques) on dose estimate. The dose map created 
through the MRI convolved with the PET PSF was shown to accurately predict and 
match the PET-based dose map as shown through voxel-by-voxel and DVH comparison. 
Additionally, this study demonstrated that spatial resolution effects dose results 
calculated using image based dosimetry methods, specifically lowering the maximum 
dose values where distributions occur with large gradients.  It is expected the more 
uniform the source is, the less profound this effect would be.  
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5.5 Conclusions 
This study demonstrates the feasibility of using polymer gel dosimetry for verification of 
voxel based 90Y dosimetry created using imaging, such as PET/CT.  With the use of this 
technique, future research can be conducted in optimizing imaging protocols for 90Y 
dosimetry in heterogeneous concentrations as found following radioembolization. 
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CHAPTER 6. MONTE CARLO SIMULATION WITH 90Y PET/CT INPUTS 
PREDICTS EXTERNAL DOSE RATES SURROUNDING PATIENTS 
FOLLOWING RADIOEMBOLIZATION  
6.1 Introduction  
Historically there has been little concern about external dose rates around patients 
following radiotherapy with  - emitting isotopes, such as 90Y, due to the short range of 
the  - particles resulting in low exposure rates outside the patient.  However, 
bremsstrahlung photons produced by the slowing down of the  - particles can result in 
exposure to others and should be evaluated.  In the United States, the Nuclear Regulatory 
Commission (NRC) and agreement states regulate the release of patients who have 
received byproduct radionuclide material, such as 90Y, to ensure adequate radiation safety 
to members of the public who may be exposed to radiation from patients following 
treatment.  Pursuant to title 10 of the Code of Federal Regulations (CFR) Part 35.75, or 
agreement state equivalent, a hospital may only release a patient if it is not likely that any 
other individual could receive a total effective dose equivalent (TEDE) of 5 mSv from 
exposure to the released individual. Additionally, the hospital must provide instructions 
to the released individual to maintain radiation exposure levels to other individual as low 
as is reasonably achievable (ALARA) if the TEDE to any other individual is likely to 
exceed 1 mSv. 
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10 CFR 20.1003 defines TEDE as the sum of external dose equivalent (EDE) and internal 
radiation exposure.  As the majority of the 90Y glass microspheres become permanently 
lodged in the liver, internal radiation exposure to individuals other than the patient can be 
assumed to be negligible(66).  Resin microspheres (SIR-spheres®) have trace amounts of 
free 90Y on the surface which can lead to small amounts of excretion through urine, but 
internal radiation exposure is still expected to be minimal following appropriate 
precautions such as washing hands after urination(20). The only concern for internal 
radiation exposure following radioembolization would be breast feeding, which is not 
considered in this study.  
EDE is defined as the sum of the products of the dose equivalent to individual organs and 
tissues and the weighting factors applicable to those tissues.  Assuming the individual is 
exposed to the whole body, the tissue weighting factor becomes 1 and EDE is simplified 
to the dose equivalent to the whole body, making EDE equivalent to the historically used 
dose term deep dose equivalent (DDE).  The recommended equation to calculate DDE 
following patient release is: 
Equation 6.1 
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where DDE is in mSv; Ro is the dose rate at 1 m from the patient in mSv hr-1; Tp is the 
physical half-life in days (2.67 days for 90Y); E is the fraction of time a person is 
expected to be within a certain distance from the released patient, known as the 
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occupancy factor; and r is the distance from the patient in meters. R0 currently is 
determined by either survey measurement or the following calculation,   
Equation 6.2 
 

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, 
where

 is the bremsstrahlung constant in soft tissue,  1.52 x 10-3 mSv cm-2 MBq-1 hr-1, 
and Qo is the administered activity(67). If a survey measurement is used, it is generally 
taken at 1 m above the surface of the patient. The occupancy factor and distances are 
generally based on the NRC recommended general public scenario, which assumes an 
individual is present at 1 m distance from the patient for 6 hours a day (E= 0.25)(68).  
More restricted scenarios for caregivers proposed by Siegel et al.(69) are shown in table 
6.1. 
Table 6.1 Exposure scenerios used to calculate dose to individuals following patient 
release 
Scenario Occupancy Factor (E) Distance (m) 
NRC General Public 0.25 1 m 
Caregiver 0.25 0.3 m 
Significant Caregiver 0.5 0.3 m 
 
In a study published by Gulec et al. in 2007, a linear source assumption was 
recommended to convert 
 

 measured at 1 m to dose rates at distances less than 1 m(70). 
This linear source assumption was based on dose measurements provided in the SIR-
sphere training manual which found doses of 18.8, 9.2, and 1.5 μSv/hr at 0.25, 0.5, and 1 
m from a patient who received 2.1 GBq of 90Y during treatment.  From these 
measurements, the correction factor, based upon a linear dose model assumption, was the 
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new distance, expressed in cm, divided by 3.  Using this assumption, the DDE can be 
estimated using equation 6.3 in scenarios requiring distances shorter than 1 m: 
Equation 6.3 
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Using this equation with the bremsstrahlung constant, 1.52 x 10-3 mSv cm2 MBq-1 hr-1, it 
was found that an activity level of at least 14.3 GBq would be required to exceed the 
lower limit of 1 mSv using the most restrictive scenario, the significant caregiver. Gulec 
et al. stated that the maximum treatment dose is around 9 GB and therefore the regulatory 
thresholds are never expected to be met following radioembolization.   
However, in a recent study published in 2012 by McCann et al, 15.7% (3/19) of dose 
rates found around patents led to a calculated TEDE exceeding the 1 mSv threshold 
following TheraSphere® radioembolization assuming the significant caregiver scenario 
and using dose rates measured at a distance of 0.3 m instead of 1 m. The highest activity 
administered in this study was 5.14 GBq, significantly lower than 14.3 GBq.   
It is hypothesized that the difference between the findings of these studies is due to the 
method used to estimate dose rate at 0.3 m. Although the linear source assumption may 
be correct in some cases, it was believed that the dose rate distributions around patients 
will vary and may be dependent on the direction the measurement is taken around a 
single patient.  Additionally, variation in the distance the bremsstrahlung photons have to 
travel to escape the body is believed to change the bremsstrahlung constant.  
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In this study, we will demonstrate the feasibility of a new method to determine dose rate, 
R0, around patients following radioembolization by incorporating quantitative 90Y PET 
images, with associated CT images for shielding, into a MC simulation.  The simulated 
dose rate results will be used to estimate dose to other individuals who are in close 
proximity to patients released from hospitals after radioembolization and evaluate the 
applicability of the linear source assumption and the 90Y bremsstrahlung constant.  
6.2 Materials and Methods 
6.2.1 Image Acquisition 
Dose rates around 10 patients were simulated in this study.  Only patients with 1 bed 
position acquisitions were used to minimize computational resources. PET images were 
acquired and reconstructed as described in chapter 4.   
6.2.2 Monte Carlo Simulation 
MCNP5 was used to simulate the production and transport of bremsstrahlung photons.  
MCNP is a general purpose, continuous energy MC radiation transport code developed at 
Los Alamos National Laboratory(71).  MCNP5 was used due to its repeated structure 
feature, allowing CT images to be converted into a heterogeneous hexahedra lattice 
structure based on a subgrouping of the tissue.  To meet MCNP memory requirements, 
CT arrays, originally 512x512, were bilinear resampled to 123x123 using ImageJ(72).  
The resampled CT image was then converted to a MCNP input card using an in house 
conversion program written in IDL.  This program grouped materials into 6 bins based on 
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CT Hounsfield units (HU) based on a method validated in DeMarco et al. study (Table 
2)(73).  Since localized density differences inside the body would have minimal impact 
on external dose rates, one density value was used for each material group.  Besides lung 
tissue, density and weight fractions of each material was gathered from ICRU44(74).  
The lung density was set to the mean lung density found in the DeMarco et al. study.  
Table 6.2 Tissue groupings based on CT Hounsfield units (HU) for MCNP input 
Material HU Numbers Density [g cm-3] 
Air <-930 0.00120479 
Lung -930:-200 0.35 
Fat -200:-5 0.95 
Water -5:5 1.1 
Muscle 5:280 1.05 
Bone 280:1000 1.92 
 
Voxel activity from the PET DICOM array was used as the MCNP source term.  Using 
the in-house conversion program, a point source was created at the center of each PET 
voxel with the source probability set to the PET measured activity.  A point source was 
deemed reasonable to replace voxel volumetric sources (0.4x0.4x0.3mm) to minimize 
computational resources since exposure rates were measured outside the body at a 
minimum of 0.3 m away.  
As described in chapter 4, the low SNR of 90Y leads to high MDA and positive bias 
following commercial iterative reconstruction.  To limit the effect of the positive bias, a 
radiologist defined contour of the treated lobe was used to create a volume of interest 
(VOI) where the 90Y microspheres are trapped during the treatment.  A threshold was 
used to match the VOI activity to the liver to remove the positive bias(75).  All PET 
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activity measured outside the treated lobe VOI and that found below this threshold was 
set to zero before defining the source.   
Dose rates were determined at 0.3, 0.5, and 1 m away from the surface of the patients’ 
body in the anterior and posterior direction, directly above and below the treated lobe. 
Additionally, dose rates were determined at the same distances to the sides of the patient. 
Locations were selected based on location of the highest activity found in the PET scans. 
The patient boundaries were defined on the CT images associated with the PET images. 
An energy deposition tally, F6 type, was used to determine the average energy deposited 
over a detector with a 1 x 5 cm detector face, with the z-axis (sagittal) having the 5 cm 
dimension. This energy deposition was converted to a dose rate through the following 
equation: 
Equation 6.4 
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where Ed is the energy deposited in MeV g-1 and A is 90Y activity in the liver in Bq, and t 
is time in s.  
6.2.3 Dose Rate Verification 
Eight (8) dose rate measurements were collected from the first day acquisition of the 
phantom described in Chapter 2.  The survey was conducted with a Ludlum model 19 
microR survey meter.  The survey locations were at 0.3 and 1 m in four different 
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directions, directly above and below and to the right and left. The phantom DICOM 
images were imported into the MCNP input file in a similar manner as a patient data set.    
6.3 Results 
Phantom simulation results demonstrate the feasibility of using MC simulations with 
PET/CT images to predict dose rate measurements for 90Y (Table 6.3). The simulated 
phantom dose rates had an average percent error of 5.9±3.5% and 3.3±5.4% for measured 
dose rates at 0.3 and 1 m, respectively.   
Table 6.3 Measured and simulated dose rate results from phantom acquisition 
 Dose Rates at 0.3 m (μSv/hr) Dose rates at 1 m (μSv/hr) 
Dose rate 
Point 
Measured Simulated Measured Simulated 
Top 2.5 2.3 0.31 0.31 
Bottom 2.9 2.8 0.34 0.33 
Left 2.2 2.1 0.24 0.24 
Right 2.2 2.0 0.21 0.19 
 
Table 6.4 provides the dose calculated from the simulation dose.  As shown, dose rates 
were found to be highly variable around the patients, with the maximum dose found 
above 1 patient, below 3 patients, and to the right of 6 patients.  As expected, in no case 
was the highest value on the left side of the patient. As shown in figure 6.1, the maximum 
measured dose rate found in the simulation at 1 m from the patient was always higher 
than that calculated using the bremsstrahlung constant.  The average difference between 
the simulated and calculated dose rate was 0.5 ± 0.4 μSv/hr. 
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Table 6.4 Dose rates at 1 m from patient boundary in 4 directions found through 
simulation and calculated using   constant 
Patient Activity (GBq) 
Dose Rate at 1 m (μSv/hr) 
Above Below Right Left  calculation 
1 1.3 0.2 0.3 0.4 0.1 0.2 
2 1.6 0.4 0.5 0.8 0.1 0.2 
3 1.8 1.4 0.1 1.0 0.2 0.3 
4 2.1 0.2 0.3 0.5 0.1 0.3 
5 2.1 0.4 0.6 0.4 0.1 0.3 
6 2.1 0.4 0.3 0.4 0.1 0.3 
7 2.7 0.7 0.9 0.6 0.1 0.4 
8 2.7 0.3 0.6 0.6 0.1 0.4 
9 3.1 0.7 1.0 1.2 0.2 0.5 
10 3.9 1.2 1.5 2.0 0.2 0.6 
 
 
Figure 6.1 Comparison of the maximum dose rates found through simulation and 
calculated using 
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Using the maximum dose rate found at 1 m from the patient, the average dose was 0.02 
+/- 0.01 mSv for the NRC general public scenario, with none of the calculated doses 
coming close to the 1 mSv threshold.  Additionally, no simulated dose rate was found 
that resulted in dose exceeding the 1 mSv threshold for the caregiver scenario and no 
cases came close to exceeding the 5 mSv threshold for any dose scenarios. However, 1 
dose rate was found to result in a dose exceeding the 1 mSv threshold when the most 
restrictive scenario, the significant caregiver, was used. The average significant caregiver 
dose was found to be 0.4 +/- 0.2 mSv.  
Table 6.5 Dose to other individuals calculated using various scenerios for the 10 patients 
analyzed based on dose rates found through the simulation based 
Patient 
Dose (mSv) 
General 
Public 
Caregiver
 
Significant 
Caregiver 
1 0.01 0.1 0.2 
2 0.02 0.1 0.3 
3 0.03 0.5 1.0 
4 0.01 0.2 0.3 
5 0.01 0.2 0.3 
6 0.01 0.2 0.3 
7 0.02 0.2 0.5 
8 0.01 0.2 0.4 
9 0.03 0.2 0.3 
10 0.05 0.2 0.5 
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Figure 6.2 Simulated dose rates found at a) 0.3 and b) 0.5 m compared with calculated 
dose rates determined using the linear assumption correction factor with the dose rate 
calculated at 1 m using the bremsstrahlung constant. Simulated dose rates at c) 0.3 and d) 
0.5 m compared with the dose rates calculated using the linear assumption correction 
factor with the simulated dose rates found at 1 m.  
6.4 Discussion 
This study demonstrates PET/CT DICOM images can be used as inputs into a MCNP 
simulation to estimate dose rates surrounding a patient following 90Y radioembolization. 
The MCNP simulation provides dose estimates at any location around the patient, 
including underneath a patient, which may be difficult to do by survey measurements 
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immediately following radioembolization procedures because patients need to remain in a 
laying position for approximately 6 hours.  
The simulated doses around the patient demonstrated that the linear dose rate assumption 
and bremsstrahlung constant do not provide conservative estimates for the dose rates 
surrounding patients in the majority of instances.  Therefore, this study provides evidence 
that measurements, either through survey or simulation, should be collected at all 
locations which DDE is to be determined when deciding whether or not to provide patient 
instructions as required per regulations.  As dose rates were found in this study to 
produce DDE close and sometimes greater than 1 mSv in some situations, it is 
recommended that patients receive instructions to keep exposure to their caregivers and 
family members ALARA. However, as the DDE was not shown to exceed or approach 
the 5 mSv value, this study provides additional support that dose rates surrounding 
patients following radioembolization should not prohibit patient release. 
The simulation values demonstrate that the highest dose rate is not always above the 
patient.  This study showed that the dose rates can be highly variable in different 
directions around the patient due to the distribution of the 90Y and tissue shielding.  
Future use of the simulation could allow for patient specific instructions detailing the best 
locations which their caregivers or family members should be while in close proximity to 
the patient to maintain doses ALARA.  
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6.5 Conclusion 
This study demonstrated the feasibility of using 90Y PET/CT images as input into a MC 
simulation to determine dose rates surrounding a patient following radioembolization.  
Through evaluation of a small group of patients, the simulated dose rates clearly showed 
the previously suggested linear source assumption and bremsstrahlung constant should 
not be used to conservatively calculate dose to other individuals around the patient 
following treatment. Although the simulated dose values further demonstrated dose rates 
surrounding patients are unlikely to exceed the 5 mSv threshold for patient release, this 
study did show instructions may be necessary prior to release of some patients.  In 
addition, this study demonstrated the usefulness of using imaging results as input data 
into MC simulations to generate detailed patient specific external radiation exposure 
rates.   The external exposure rate information will facilitate the development of caregiver 
instructions in order to keep doses to other individuals ALARA. 
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CHAPTER 7. PATIENT RESULTS FROM 90Y PET/CT DOSE MAPS  
7.1 Introduction 
As stated in chapter 1, historically there have been no means to determine the 
microsphere distribution found in the liver following radioembolization and gross 
assumptions, such as assuming uniform lobe distribution, are used to determine 
dosimetry.  One such assumption used is to assume uniform distribution across the 
treated lobe, which is known to be false as one of the reasons radioembolization is so 
successful is due to the preferential targeting of tumor volume.  The following section 
provides a small portion of patient dosimetry results found with the 90Y PET/CT images 
collected at IU health downtown university hospital, demonstrating the use to provide 
patient specific dosimetry for future research and clinical use.  
7.2 Materials and Methods 
The patient images described in chapter 4 were contoured and aligned using MIM 
software by a radiologist at IU Health Downtown hospital so dose results to the normal 
liver parenchyma and tumors greater than 1 cm could be analyzed.  In studies with large 
necrotic centers, the tumors were contoured to differentiate between viable and non-
viable tumor volumes. Healthy normal tissue parenchymal contours were constructed by 
removing tumor volumes from the treated lobe contours. Contour dose, volume, and 
94 
 
DVHs were gathered from the dose maps using MIM. These were compared against the 
empirical dose calculated using the TheraSphere package insert dosimetric equation,  
Equation 7.1 
  
 

, 
where A is activity in GBq and m is the mass of the treated lobe, determined based on the 
volume of the treated lobe contour in MIM and converted using liver density of 1.03 
g/ml.  
As described in Chapter 2, positive bias is present in these images when voxels contain 
less than the MDC of 1 MBq/ml.  Conservatively assuming all energy from 1 MBq of 90Y 
is deposited over the 1 ml, the MDC was converted to dose of 48.4 Gy using the 
following equation: 
Equation 7.2 
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, 
where A is the activity 1 MBq and m is the mass of the liver for 1 ml, which is 1.03 g. 
Since positive bias was observed only at concentrations below the MDC, the DVH curve 
was analyzed for doses only greater than 48.4 Gy.  
7.3 Results 
The mean percent difference between measured tumor and prescribed dose was 9.7 +/- 
94.6%, with 79 of the 111 lesions having calculated dose exceeding the prescribed. The 
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mean percent difference between calculated parenchyma and prescribed doses was -
10.5% +/- 19.4%, with 8 of the 63 studies having calculated dose exceeding the 
prescribed and average patient tumor doses. 
On a voxel level, the average of 37% +/- 14.8 of parenchymal voxels had measured dose 
exceeding the prescribed calculated using equation 7.1.  On average, 77% of the 
parenchymal voxels (SE ± 2.1%) received greater than 50 Gy. Additionally, 35% (SE ± 
3.0%) received greater than 100 Gy, 15% (SE ± 5.2%) received greater than 150 Gy, and 
6% (SE ± 8.5%) received greater than 200 Gy(76).  
7.4 Patient Result Conclusions 
These patient results demonstrate the need to determine microsphere distribution 
following radioembolization as the assumption of uniform dose is shown to be false. 
These results show that in the majority of treatments, the lesion volume received higher 
dose than the parenchymal volume.  However, 12.7% (8/63) the parenchyma was found 
to receive a higher average dose as compared to the tumor volume. With future research, 
as described below, the dosimetry information provided by these PET dose maps might 
be able to predict tumor response and complication rates on a patient specific basis. 
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CHAPTER 8. CONCLUSIONS AND FUTURE WORK 
8.1 Summary 
Radioembolization is a novel therapy used in treating liver cancers, such as HCC, 
which utilizes the livers unique blood supply to deliver 90Y microspheres.  As the 
microspheres travel from the injection point in the hepatic artery, they distribute in a 
heterogeneous fashion as they become trapped in the liver’s microvasculature, 
resulting in a heterogeneous liver dose.  The therapeutic objective is to have the 
majority of the 90Y microspheres deposit inside or close to the tumors, resulting in a 
high dose to tumors while sparing normal, radiation sensitive, liver tissue.  The exact 
distribution and dosimetry is difficult to predict without knowledge of individual 
patient’s specific blood supply and microsphere distribution.  Therefore, gross 
assumptions, such as uniform distribution of the microspheres, have been made in 
order to make simple dosimetry estimates.  
In 2009, PET imaging was shown to be a feasible method for displaying patient 
specific microsphere distribution following radioembolization.    The very small 
internal pair production rate of 90Y and the large doses used in the therapy provides 
sufficient signal for the generation of PET images.  Following the original report, 
numerous studied have been published demonstrating the feasibility of using PET to 
quantitatively measure the 90Y activity (28-30) and dose (32, 33).  However, 
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few studies have carefully evaluated the quantitative limitations of 90Y PET 
associated with the unique decay characteristics of this radionuclide.  This study was 
conducted to evaluate the 90Y signal and the accuracy of the 90Y PET images and 
dosimetry using various PET reconstruction techniques and gel dosimetry to further 
advance the use of PET imaging for patient specific, intra-organ dosimetry following 
radioembolization. The summary of the specific aims of this work are provided 
below. 
1) Evaluate the effects various reconstructions algorithms have on the accuracy and 
limitations of 90Y PET/CT imaging. 
As demonstrated in Chapter 2, the parameters used in image reconstruction 
substantially affect the accuracy and noise of 90Y PET/CT imaging. Due to the 
unique low signal, two commonly used reconstruction techniques in quantitative 
reconstruction were found to lead to reduced accuracy. First, smoothing random 
sinograms, which is generally desired to reduce variance in random counts, was 
found to underestimate 90Y activity likely due to inadequate random correction in 
the sinogram tails leading to erroneously high scatter corrections. Second, closed 
form DiFT reconstruction led to minimum detectable concentration (MDC) 
above which is generally found in the treated lobe following radioembolization 
due to the reconstruction’s inability to reduce noise.  This study determined the 
optimal reconstruction protocol for the Siemens® Biograph 64 PET/CT for 90Y 
is 2i14s using commercial TrueX iterative reconstruction to provide a balance 
between MDC limitations, quantitative accuracy, and SNR. 
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2) Determine origin of 90Y PET coincident count signal and noise to support 
appropriate reconstruction techniques.  
Through use of a GATE model this study showed the origin of the 90Y 
coincidence counts on the Siemens® Biograph TruePoint 64 PET/CT.  This 
study demonstrated the extremely poor SNR assoicated with 90Y imaging, even 
at concentrations used in therapy.  Unlike imaging with higher positron emission 
rates, the random coincidence  noise was shown to increase linearly with activity.  
This increase in random coincidence counts was found to be due to coincedence 
counts assoiciated with one photon from bremsstrhalung and one count from 
176Lu.  
3) Evaluate the effect of positive bias observed in 90Y PET/CT using standard 
clinical iterative algorithm techniques for reconstruction following sinogram 
truncation.  
As demonstrated in the previous aim, 90Y has extremely poor counting statistics.  
This led to a positive bias where the concentration is less than the MDC due to 
truncation of negative sinogram ray-bin values during reconstruction.  This study 
demonstrated that this positive bias did not affect image accuracy in areas where 
concentration was above the MDC, which is generally the case in most tumors.  
However, due to the heterogeneous distribution across the treated lobe, it was 
shown that most patients had large areas of the parenchyma where the 
concentration was below the MDC, resulting in erroneously high PET activity 
and dose results for the parenchymal region.  Therefore, this study demonstrated 
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that while PET images may be used to determine tumor dose, care must be taken 
when analyzing dose to regions with low concentration.   
4) Validate 90Y PET/CT dose maps created using a standard S-kernel using gel 
dosimetry. 
This study demonstrated MAGIC polymer gel dosimetry can feasible provide a 
validation method for 90Y heterogeneous dosimetry using MRI.  Through voxel-
by-voxel and DVH comparison with MRI dose map convolved with the PET 
PSF to match spatial resolution, the gel dosimetry demonstrated that 90Y PET/CT 
imaging provide accurate, but noisy, dose maps using standard S-kernel 
convolution.  However, the comparison of the original MRI and PET/CT dose 
maps demonstrated the limitations of the PET/CT dose maps due to spatial 
resolution leading to the spreading of the dose values, reducing the maximum 
dose measurement, in areas where 90Y activity is highly heterogeneous.  
5) Use PET/CT 90Y activity distribution maps to verify line source assumption used 
in patient release surveys.  
In addition to displaying internal dosimetry, 90Y PET/CT images were found to 
feasibly provide dose rates surrounding a patient following radioembolization by 
being used as input into a MC simulation.  Through use of a phantom, the PET 
images where shown to have a doses rate accuracy of 10%. In line with previous 
studies, the simulation results demonstrated that dose rates surrounding patients 
are unlikely to exceed the 5 mSv threshold for patient release. This study 
provided an additional use for 90Y PET/CT images as it demonstrated that 
100 
 
 
imaging could be used to create patient-specific dose rate maps around patients 
following radioembolization, which in turn would enable the provision of better 
instructions to keep doses to other individuals ALARA.  
8.2 Future Work 
As shown throughout this work, the small positron emission from 90Y allows for 
PET/CT imaging to provide distribution maps and dosimetry following 
radioembolization.  As demonstrated in chapter 2, careful consideration is needed to 
optimize acquisition and reconstruction protocols for 90Y imaging due to the very 
small true signal compared to random noise. This work demonstrated TrueX iterative 
algorithm using 2 iterations and 14 subsets following net acquisition with DRCC was 
the optimal protocol to balance image accuracy and noise for the Siemens® Biograph 
64 TruePoint PET/CT system.  As 90Y has an extremely small PET signal, small 
differences in scanner geometries, crystal materials and manufacturer correction and 
reconstruction algorithms, which generally do not cause large changes while imaging 
typical PET isotopes, could have large effects in 90Y imaging. Therefore, an 
evaluation should be completed for each type of PET scanner to determine an optimal 
reconstruction protocol prior to conducting 90Y PET/CT imaging for quantification 
purposes.  
With a known source distribution there is significant potential to enhance 
radioembolization treatments.  As stated in the introduction, current knowledge of 
intra-liver dosimetry is very limited.  As a result, there is no method to predict tumor 
response following treatment.  However, with the use of post therapy imaging, studies 
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are starting to evaluate whether dose can predict tumor response.  Tumor response 
from our patient population was analyzed with our PET dose maps by a radiologist 
where he found that the fraction response by the tumors improved drastically when 
the tumors received greater than 150 Gy and that complete response (as measured 
using mRECIST criteria) occurs 90% of the time when the whole tumor received 150 
Gy, 75% of the tumor received 200 Gy, or 51% of the tumor received 250 Gy(77). 
Unfortunately, tumor response is likely controlled by many variables, such as size of 
the tumor, presence of necrotic volume, and blood flow, resulting in differences in 
how tumors respond. Therefore, future research is necessary to enable treatment 
planning - on a patient specific basis.  
Additionally, severe complications, such as radioembolization induced liver disease 
(ReILD) described in the introduction, does occur following treatment in some 
patients.  As radiation induced damage to the liver depends on the amount of 
radiation normal, healthy tissue receives, without patient specific dosimetry it is 
difficult to predict which patients are likely to have complications.   With PET dose 
maps, it may be possible to determine the probability which ReILD might occur. 
Additionally, future studies could determine if the probability of complications is 
different from external beam radiotherapy. It is currently theorized that the liver is 
withstanding the higher dose used in radioembolization treatment due to several 
factors including embolization causing lower oxygen concentrations for “setting” D 
damage, exposure being received at lower dose rates allowing for repair mechanisms, 
and dose distribution resulting in sparing of significant volume of healthy tissue in 
radioembolization as compared to external beam treatments.   
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Unfortunately, tolerance doses of the whole liver found in studies conducted using 
external beam therapy are lower than 50 Gy, the approximate minimum dose that can 
accurately be measured due to the high image MDC of approximately 1 MBq/ml.   
Therefore, comparison of healthy liver response for whole liver exposures could not 
be completed unless PET SNR is increased. However, as radioembolization therapies 
exposure is localized, as seen from patient results in chapter 4, the fractional volume 
of healthy tissue which is expected to be exposed to doses greater than 50 Gy is 
generally smaller than the entire liver.  As has been shown through external beam 
therapy studies, the smaller the portion of the liver exposed, the higher the tolerance 
dose.  For example, if only two-thirds of the liver is exposed, the tolerance dose raises 
to 60 Gy for patients being treated for HCC(78). Therefore, it is believed that 90Y 
PET images discussed in this work could be used to compare tolerance doses between 
radioembolization and external beam therapy.  
In addition to using 90Y PET to predict outcomes from treatments, it could also be 
used to support future research to determine if radioembolization treatment planning 
is possible. As stated in chapter 1, a 99mTc-MAA SPECT is taken approximately 2 
weeks before treatment to grossly estimate where the microspheres will deposit.  
However, without post therapy images demonstrating where the microspheres truly 
deposit, it is uncertain if the MAA actually deposit in a similar manner as the 
microspheres.  With the post therapy PET images, correlation between the 
distributions could be determined.  Additionally, factors such as catheter tip position 
and injection flow could be evaluated to determine if they effect the correlation.  
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MAA and microspheres distribution may not correlate due to differences in size and 
density even if they are injected in the exact same manner. Unfortunately, due to the 
PET limitation of a 1 MBq/ml MDC, a diagnostic scan using current PET 
reconstruction and correction protocols would not be possible using the current 90Y 
microspheres.  Therefore, future work would be necessary to either increase the signal 
or decrease the noise in the acquisition before microsphere distribution could be 
determined using diagnostic activity.  As shown in chapter 3, much of the 
coincidence count noise arises from the natural radioactivity in the Lu based crystals.  
Therefore, future studies could be used to evaluate whether PET machines with non-
Lu based crystals, such as BGO, have better SNR resulting in lower MDC 90Y PET.  
However, LSO crystals are generally used due to their high sensitivity, so it is 
uncertain if the reduced random counts would result in significantly better SNR and 
therefore images. 
It is therefore believed that increasing the signal may be a better option to increase 
90Y PET SNR. One possible technique which may increase the microsphere signal is 
to tag or mix the microspheres with a radioisotope with a larger fraction of positron 
emission, like 18F.  This would allow for diagnostic scan using microspheres with the 
same characteristics as used during treatment to predict the distribution of the 90Y 
microspheres during radioembolization.  The current 90Y post therapy PET could then 
be used to verify that diagnostic and therapy distributions match. If they were shown 
to match, the diagnostic images could be changed to dose predictions, allowing for 
patient specific activity planning.  Treatment planning could then balance probability 
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of successful tumor response with possible complications enhancing the 
effectiveness, and the safety, of 90Y microsphere radioembolization.  
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